{
  "$schema": "folio-library-document/v1",
  "id": "10665-350214",
  "title": "Comprehensive package of care for infants and young children exposed to HIV: policy brief",
  "variant": "pdf",
  "pages": 34,
  "tocSource": "inferred",
  "tocMethod": "font",
  "toc": [
    {
      "level": 1,
      "title": "POLICY BRIEF",
      "number": null,
      "page": 2,
      "pageLabel": "2",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-policy-brief"
    },
    {
      "level": 1,
      "title": "COMPREHENSIVE PACKAGE OF CARE FOR INFANTS AND YOUNG CHILDREN EXPOSED TO HIV",
      "number": null,
      "page": 2,
      "pageLabel": "2",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-comprehensive-package-of-care-for-infants-and-yo"
    },
    {
      "level": 2,
      "title": "3TC",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-3tc"
    },
    {
      "level": 2,
      "title": "ART ARV AZT CTX",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 2,
      "title": "LPV/r",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-lpvr"
    },
    {
      "level": 2,
      "title": "NAT NNRTI NVP PNP RAL UNICEF",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 1,
      "title": "ABBREVIATIONS",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.8,
      "evidence": [
        "style",
        "numbered-style",
        "stock-name"
      ],
      "source": "inferred",
      "section": "sec-004-abbreviations"
    },
    {
      "level": 1,
      "title": "ACKNOWLEDGEMENTS",
      "number": null,
      "page": 4,
      "pageLabel": "1",
      "confidence": 0.8,
      "evidence": [
        "style",
        "numbered-style",
        "stock-name"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 2,
      "title": "Justification for the comprehensive package of care for infants and young children exposed to HIV",
      "number": null,
      "page": 5,
      "pageLabel": "2",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-006-justification-for-the-comprehensive-package-of-c"
    },
    {
      "level": 1,
      "title": "BACKGROUND",
      "number": null,
      "page": 5,
      "pageLabel": "2",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-005-background"
    },
    {
      "level": 2,
      "title": "Overview of the interventions along the continuum of care",
      "number": null,
      "page": 6,
      "pageLabel": "3",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-007-overview-of-the-interventions-along-the-continuu"
    },
    {
      "level": 2,
      "title": "Components of the comprehensive package of care for infants and young children exposed to HIV",
      "number": null,
      "page": 6,
      "pageLabel": "3",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-008-components-of-the-comprehensive-package-of-care"
    },
    {
      "level": 2,
      "title": "Scope",
      "number": null,
      "page": 6,
      "pageLabel": "3",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-009-scope"
    },
    {
      "level": 3,
      "title": "Infant diagnosis",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-infant-diagnosis"
    },
    {
      "level": 3,
      "title": "Postnatal care",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-postnatal-care"
    },
    {
      "level": 3,
      "title": "Maternal testing, treatment and monitoring",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-maternal-testing-treatment-and-monitoring"
    },
    {
      "level": 3,
      "title": "Postnatal prophylaxis",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-postnatal-prophylaxis"
    },
    {
      "level": 3,
      "title": "Co-trimoxazole",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-015-co-trimoxazole"
    },
    {
      "level": 3,
      "title": "Nurturing care",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-016-nurturing-care"
    },
    {
      "level": 3,
      "title": "HIV",
      "number": null,
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-hiv"
    },
    {
      "level": 3,
      "title": "PNP",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-017-pnp"
    },
    {
      "level": 3,
      "title": "ID",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 3,
      "title": "NC",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-018-nc"
    },
    {
      "level": 3,
      "title": "CTX",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-019-ctx"
    },
    {
      "level": 3,
      "title": "HIV-POSITIVE DIAGNOSIS",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-020-hiv-positive-diagnosis"
    },
    {
      "level": 4,
      "title": "ART",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-021-art"
    },
    {
      "level": 4,
      "title": "Routine",
      "number": null,
      "page": 9,
      "pageLabel": "6",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-022-routine"
    },
    {
      "level": 1,
      "title": "\u0007MATERNAL HIV TESTING, TREATMENT AND MONITORING",
      "number": "1",
      "page": 10,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-023-1-maternal-hiv-testing-treatment-and-monitoring"
    },
    {
      "level": 2,
      "title": "Maternal HIV testing and retesting",
      "number": "1.1",
      "page": 11,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-024-11-maternal-hiv-testing-and-retesting"
    },
    {
      "level": 3,
      "title": "Settings with a high burden of HIV infection",
      "number": null,
      "page": 11,
      "pageLabel": "8",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-025-settings-with-a-high-burden-of-hiv-infection"
    },
    {
      "level": 3,
      "title": "Settings with a low burden of HIV infection",
      "number": null,
      "page": 11,
      "pageLabel": "8",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-026-settings-with-a-low-burden-of-hiv-infection"
    },
    {
      "level": 2,
      "title": "Implementation considerations",
      "number": null,
      "page": 12,
      "pageLabel": "9",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-027-implementation-considerations"
    },
    {
      "level": 3,
      "title": "Time points",
      "number": null,
      "page": 12,
      "pageLabel": "9",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-028-time-points"
    },
    {
      "level": 2,
      "title": "Viral load monitoring",
      "number": "1.2",
      "page": 13,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-029-12-viral-load-monitoring"
    },
    {
      "level": 3,
      "title": "Category",
      "number": null,
      "page": 13,
      "pageLabel": "10",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-030-category"
    },
    {
      "level": 3,
      "title": "Timing of viral load monitoring",
      "number": null,
      "page": 13,
      "pageLabel": "10",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-031-timing-of-viral-load-monitoring"
    },
    {
      "level": 3,
      "title": "Action",
      "number": null,
      "page": 13,
      "pageLabel": "10",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-032-action"
    },
    {
      "level": 3,
      "title": "Point-of-care viral load testing",
      "number": null,
      "page": 14,
      "pageLabel": "11",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-033-point-of-care-viral-load-testing"
    },
    {
      "level": 2,
      "title": "Implementation considerations",
      "number": null,
      "page": 14,
      "pageLabel": "11",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-034-implementation-considerations"
    },
    {
      "level": 3,
      "title": "care viral load testing",
      "number": null,
      "page": 14,
      "pageLabel": "11",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 3,
      "title": "Early infant diagnosis for high-risk infants",
      "number": null,
      "page": 15,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-035-early-infant-diagnosis-for-high-risk-infants"
    },
    {
      "level": 3,
      "title": "Point-of-care infant diagnosis",
      "number": null,
      "page": 15,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-036-point-of-care-infant-diagnosis"
    },
    {
      "level": 1,
      "title": "\u0007INFANT DIAGNOSIS",
      "number": "2",
      "page": 15,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-037-2-infant-diagnosis"
    },
    {
      "level": 2,
      "title": "care infant diagnosis",
      "number": null,
      "page": 15,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": null
    },
    {
      "level": 1,
      "title": "INFANT ANTIRETROVIRAL PROPHYLAXIS",
      "number": "3",
      "page": 17,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-038-3-infant-antiretroviral-prophylaxis"
    },
    {
      "level": 2,
      "title": "Risk assessment of infants exposed to HIV",
      "number": null,
      "page": 17,
      "pageLabel": "14",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-039-risk-assessment-of-infants-exposed-to-hiv"
    },
    {
      "level": 2,
      "title": "Antiretroviral prophylaxis",
      "number": null,
      "page": 18,
      "pageLabel": "15",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-040-antiretroviral-prophylaxis"
    },
    {
      "level": 3,
      "title": "Enhanced postnatal prophylaxis",
      "number": null,
      "page": 18,
      "pageLabel": "15",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-041-enhanced-postnatal-prophylaxis"
    },
    {
      "level": 2,
      "title": "Implementation considerations",
      "number": null,
      "page": 19,
      "pageLabel": "16",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-042-implementation-considerations"
    },
    {
      "level": 3,
      "title": "Providing enhanced postnatal prophylaxis to all infants exposed to HIV",
      "number": null,
      "page": 19,
      "pageLabel": "16",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-043-providing-enhanced-postnatal-prophylaxis-to-all"
    },
    {
      "level": 3,
      "title": "Extended or prolonged postnatal prophylaxis beyond",
      "number": null,
      "page": 19,
      "pageLabel": "16",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-044-extended-or-prolonged-postnatal-prophylaxis-beyo"
    },
    {
      "level": 3,
      "title": "Presumptive treatment",
      "number": null,
      "page": 20,
      "pageLabel": "17",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-045-presumptive-treatment"
    },
    {
      "level": 1,
      "title": "CO-TRIMOXAZOLE PROPHYLAXIS",
      "number": "4",
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-046-4-co-trimoxazole-prophylaxis"
    },
    {
      "level": 2,
      "title": "Population",
      "number": null,
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-047-population"
    },
    {
      "level": 2,
      "title": "Criteria for initiating co-trimoxazole prophylaxis",
      "number": null,
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-048-criteria-for-initiating-co-trimoxazole-prophylax"
    },
    {
      "level": 2,
      "title": "Criteria for discontinuing co-trimoxazole prophylaxis",
      "number": null,
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-049-criteria-for-discontinuing-co-trimoxazole-prophy"
    },
    {
      "level": 2,
      "title": "Children and adolescents living with HIV",
      "number": null,
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-050-children-and-adolescents-living-with-hiv"
    },
    {
      "level": 2,
      "title": "HIV-exposed infants",
      "number": null,
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-051-hiv-exposed-infants"
    },
    {
      "level": 2,
      "title": "Implementation considerations",
      "number": null,
      "page": 22,
      "pageLabel": "19",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-052-implementation-considerations"
    },
    {
      "level": 3,
      "title": "Infants exposed to HIV and uninfected",
      "number": null,
      "page": 22,
      "pageLabel": "19",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-053-infants-exposed-to-hiv-and-uninfected"
    },
    {
      "level": 1,
      "title": "PROMOTING NURTURING CARE",
      "number": "5",
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-055-5-promoting-nurturing-care"
    },
    {
      "level": 2,
      "title": "Responsive caregiving",
      "number": null,
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-054-responsive-caregiving"
    },
    {
      "level": 2,
      "title": "Promote early learning",
      "number": null,
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-056-promote-early-learning"
    },
    {
      "level": 2,
      "title": "Integrate caregiving and nutrition interventions",
      "number": null,
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-057-integrate-caregiving-and-nutrition-interventions"
    },
    {
      "level": 2,
      "title": "Support maternal mental health",
      "number": null,
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-058-support-maternal-mental-health"
    },
    {
      "level": 2,
      "title": "Implementation considerations",
      "number": null,
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-059-implementation-considerations"
    },
    {
      "level": 2,
      "title": "National level",
      "number": null,
      "page": 25,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-061-national-level"
    },
    {
      "level": 2,
      "title": "Human resources",
      "number": null,
      "page": 25,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-062-human-resources"
    },
    {
      "level": 2,
      "title": "Service delivery",
      "number": null,
      "page": 25,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-063-service-delivery"
    },
    {
      "level": 1,
      "title": "POLICY IMPLEMENTATION CONSIDERATIONS FOR THE COMPREHENSIVE PACKAGE OF CARE",
      "number": null,
      "page": 25,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-060-policy-implementation-considerations-for-the-com"
    },
    {
      "level": 2,
      "title": "Monitoring, evaluation and learning",
      "number": null,
      "page": 26,
      "pageLabel": "23",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-064-monitoring-evaluation-and-learning"
    },
    {
      "level": 2,
      "title": "Quality improvement",
      "number": null,
      "page": 27,
      "pageLabel": "24",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-065-quality-improvement"
    },
    {
      "level": 2,
      "title": "Research gaps",
      "number": null,
      "page": 27,
      "pageLabel": "24",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-066-research-gaps"
    },
    {
      "level": 3,
      "title": "ARV drug prophylaxis",
      "number": null,
      "page": 27,
      "pageLabel": "24",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-067-arv-drug-prophylaxis"
    },
    {
      "level": 3,
      "title": "Co-trimoxazole prophylaxis",
      "number": null,
      "page": 27,
      "pageLabel": "24",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-068-co-trimoxazole-prophylaxis"
    },
    {
      "level": 3,
      "title": "Other gaps",
      "number": null,
      "page": 27,
      "pageLabel": "24",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-069-other-gaps"
    },
    {
      "level": 1,
      "title": "REFERENCES",
      "number": null,
      "page": 28,
      "pageLabel": "25",
      "confidence": 0.8,
      "evidence": [
        "style",
        "numbered-style",
        "stock-name"
      ],
      "source": "inferred",
      "section": "sec-070-references"
    },
    {
      "level": 1,
      "title": "\u0007SIMPLIFIED AGE-BASED ANTIRETROVIRAL DRUG DOSING FOR ADMINISTERING ENHANCED AND PROLONGED POSTNATAL PROPHYLAXIS",
      "number": "Annex 1",
      "page": 31,
      "pageLabel": "28",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-071-annex-1-simplified-age-based-antiretroviral-drug"
    },
    {
      "level": 1,
      "title": "\u0007SIMPLIFIED DOSING OF CO- TRIMOXAZOLE PROPHYLAXIS FOR INFANTS AND CHILDREN AT LEAST FOUR WEEKS OLD",
      "number": "Annex 2",
      "page": 32,
      "pageLabel": "29",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-072-annex-2-simplified-dosing-of-co--trimoxazole-pro"
    },
    {
      "level": 1,
      "title": "\u0007ANNEX 3. INFANT DIAGNOSIS ALGORITHM",
      "number": null,
      "page": 33,
      "pageLabel": "30",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-073-annex-3-infant-diagnosis-algorithm"
    },
    {
      "level": 2,
      "title": "For more information, contact:",
      "number": null,
      "page": 34,
      "pageLabel": "31",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-074-for-more-information-contact"
    },
    {
      "level": 2,
      "title": "E-mail: hiv-aids@who.int www.who.int/hiv",
      "number": null,
      "page": 34,
      "pageLabel": "31",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-075-e-mail-hiv-aidswhoint-wwwwhointhiv"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 2,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 21,
      "summary": {
        "text": "The cover of the 2021 policy brief on a comprehensive package of care for infants and young children exposed to HIV.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "POLICY BRIEF COMPREHENSIVE PACKAGE OF CARE FOR INFANTS AND YOUNG CHILDREN EXPOSED TO HIV 2021 © UNICEF UNI221734 / Gonzalez Farran",
      "extractCut": false,
      "blocks": [
        "library/10665-350214/blocks/prose-sec-front-matter",
        "library/10665-350214/blocks/figure-img-p001-1"
      ]
    },
    {
      "id": "sec-000-policy-brief",
      "number": null,
      "title": "POLICY BRIEF",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-001-comprehensive-package-of-care-for-infants-and-yo",
      "number": null,
      "title": "COMPREHENSIVE PACKAGE OF CARE FOR INFANTS AND YOUNG CHILDREN EXPOSED TO HIV",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 4,
      "labelStart": "2",
      "labelEnd": "1",
      "words": 512,
      "summary": {
        "text": "The title and copyright page of WHO's 2021 policy brief on comprehensive care for infants and young children exposed to HIV, giving ISBNs, the Creative Commons licence terms, citation and cataloguing details. It also includes the standard WHO disclaimers and layout credit.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children exposed",
          "heading": true
        },
        {
          "term": "young children",
          "heading": true
        },
        {
          "term": "comprehensive package",
          "heading": true
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "infants",
          "heading": true
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "policy brief",
          "heading": false
        }
      ],
      "extract": "FOR INFANTS AND YOUNG CHILDREN EXPOSED TO HIV 2021 Comprehensive package of care for infants and young children exposed to HIV: policy brief ISBN 978-92-4-004023-6 (electronic version) ISBN 978-92-4-004024-3 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;",
      "extractCut": true
    },
    {
      "id": "sec-002-3tc",
      "number": null,
      "title": "3TC",
      "level": 2,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 10,
      "summary": {
        "text": "The start of the list of abbreviations, covering several antiretroviral drug names, therapy terms and co-trimoxazole.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "lamivudine ART antiretroviral therapy ARV antiretroviral AZT zidovudine CTX Co-trimoxazole",
      "extractCut": false
    },
    {
      "id": "sec-003-lpvr",
      "number": null,
      "title": "LPV/r",
      "level": 2,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 21,
      "summary": {
        "text": "Continues the list of abbreviations with further antiretroviral drugs, nucleic acid testing, postnatal prophylaxis and UNICEF.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pnp",
          "heading": false
        },
        {
          "term": "reverse-transcriptase",
          "heading": false
        },
        {
          "term": "nnrti",
          "heading": false
        }
      ],
      "extract": "lopinavir/ritonavir NAT Nucleic acid testing NNRTI non-nucleoside reverse-transcriptase inhibitor NVP nevirapine PNP postnatal prophylaxis RAL raltegravir UNICEF United Nations Children’s Fund",
      "extractCut": false
    },
    {
      "id": "sec-004-abbreviations",
      "number": null,
      "title": "ABBREVIATIONS",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 5,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 144,
      "summary": {
        "text": "Acknowledges the consultants who wrote the policy brief, the WHO staff who oversaw it and the partner organizations and external experts who contributed technical input.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "elizabeth glaser",
          "heading": false
        },
        {
          "term": "columbia university",
          "heading": false
        },
        {
          "term": "glaser pediatric",
          "heading": false
        },
        {
          "term": "pediatric aids",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "consultant",
          "heading": false
        }
      ],
      "extract": "This policy brief was developed by Ivy Kasirye (Consultant, WHO) and Catherine Wedderburn (Consultant, WHO), with technical oversight by Martina Penazzato and Morkor Newman Owiredu of the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes of WHO, in collaboration with UNICEF, Elizabeth Glaser Pediatric AIDS Foundation and ICAP at Columbia University. WHO gratefully acknowledges the",
      "extractCut": true
    },
    {
      "id": "sec-005-background",
      "number": null,
      "title": "BACKGROUND",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 402,
      "summary": {
        "text": "Describes the background to the policy brief, noting progress in preventing vertical HIV transmission but missed targets, with an estimated 85% of pregnant women living with HIV on treatment and 150 000 infants acquiring HIV in 2020. It stresses the need to reduce transmission risk and to support child survival, growth and development.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "hiv exposure",
          "heading": false
        },
        {
          "term": "acquiring hiv",
          "heading": false
        },
        {
          "term": "mothers living",
          "heading": false
        },
        {
          "term": "during breastfeeding",
          "heading": false
        },
        {
          "term": "viral loads",
          "heading": false
        },
        {
          "term": "suppressed viral",
          "heading": false
        }
      ],
      "extract": "of HIV, the targets for maternal antiretroviral therapy (ART) coverage and new vertical transmission have yet to be achieved (1). Globally, an estimated 85% of pregnant women living with HIV were receiving lifelong ART, and 150 000 infants acquired HIV through vertical transmission in 2020. Although more than 84% of vertical tranmissions occur in sub-Saharan Africa, it is encouraging that eastern and southern Africa",
      "extractCut": true
    },
    {
      "id": "sec-006-justification-for-the-comprehensive-package-of-c",
      "number": null,
      "title": "Justification for the comprehensive package of care for infants and young children exposed to HIV",
      "level": 2,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 424,
      "summary": {
        "text": "Justifies a comprehensive package of care by citing high losses of mothers and HIV-exposed infants between antenatal care, delivery, early testing and final diagnosis. It argues that an integrated package eases navigation for mothers and children and improves access to services for HIV-free survival.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infants exposed",
          "heading": true
        },
        {
          "term": "children exposed",
          "heading": true
        },
        {
          "term": "young children",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "multiple service",
          "heading": false
        },
        {
          "term": "care",
          "heading": true
        },
        {
          "term": "service delivery",
          "heading": false
        }
      ],
      "extract": "of care for infants and young children exposed to HIV A systematic review revealed that 49% of women living with HIV in sub-Saharan Africa are lost between antenatal care registration and delivery, 34% of infants exposed to HIV are lost to follow-up by three months and a further 45% of infants exposed to HIV are lost after their first HIV test and before definitive diagnosis (13). This highlights significant",
      "extractCut": true
    },
    {
      "id": "sec-007-overview-of-the-interventions-along-the-continuu",
      "number": null,
      "title": "Overview of the interventions along the continuum of care",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 64,
      "summary": {
        "text": "Notes that children under two routinely receive well-child services such as immunization, growth monitoring and feeding counselling, and that HIV-exposed infants also need a specific package of care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "continuum",
          "heading": true
        },
        {
          "term": "routine services",
          "heading": false
        },
        {
          "term": "deworming",
          "heading": false
        }
      ],
      "extract": "the continuum of care Children younger than two years typically receive well- child visits for routine services, including immunization, monitoring growth and development, micronutrient supplementation, deworming, preventing and managing common childhood conditions as well as infant feeding counselling and support. In addition to these routine services, infants and young children exposed to HIV should receive",
      "extractCut": true
    },
    {
      "id": "sec-008-components-of-the-comprehensive-package-of-care",
      "number": null,
      "title": "Components of the comprehensive package of care for infants and young children exposed to HIV",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 108,
      "summary": {
        "text": "Lists the maternal and infant components of the comprehensive package of care, from maternal HIV testing, treatment and monitoring to infant diagnosis, antiretroviral and co-trimoxazole prophylaxis, postnatal care, infant feeding and nurturing care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children exposed",
          "heading": true
        },
        {
          "term": "young children",
          "heading": true
        },
        {
          "term": "package",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        }
      ],
      "extract": "of care for infants and young children exposed to HIV The comprehensive package of care brings together interventions across the continuum of care that collectively aim to reduce the risk of vertical transmission of HIV and improve the health and well-being of infants and young children exposed to HIV. The package includes both maternal and infant components (Fig. 1): • \u0007maternal HIV testing and retesting: other",
      "extractCut": true
    },
    {
      "id": "sec-009-scope",
      "number": null,
      "title": "Scope",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 7,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 166,
      "summary": {
        "text": "Defines the scope of the policy brief as care for HIV-exposed infants and young children up to two years, with emphasis on maternal interventions that shape decisions about infant care. It excludes a full service package for children living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "comprehensive package",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        },
        {
          "term": "service package",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        }
      ],
      "extract": "Although the comprehensive package of care includes maternal, infant and young child interventions, this policy brief focuses mainly on the service package for infants and young children up to two years of age who are exposed to HIV. It emphasizes the maternal interventions that directly affect decision-making for interventions for the infants and young children exposed to HIV. For the detailed interventions for",
      "extractCut": true
    },
    {
      "id": "sec-010-hiv",
      "number": null,
      "title": "HIV",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-011-infant-diagnosis",
      "number": null,
      "title": "Infant diagnosis",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 15,
      "summary": {
        "text": "Describes infant diagnosis as identifying infants living with HIV promptly through repeated testing.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Timely identification of infants living with HIV by testing multiple times and ensuring infant diagnosis",
      "extractCut": false
    },
    {
      "id": "sec-012-postnatal-care",
      "number": null,
      "title": "Postnatal care",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 14,
      "summary": {
        "text": "Describes routine postnatal care, including immunization, growth and development monitoring and infant feeding support.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Routine postnatal care, including immunization, growth and development monitoring, infant feeding counselling and support",
      "extractCut": false
    },
    {
      "id": "sec-013-maternal-testing-treatment-and-monitoring",
      "number": null,
      "title": "Maternal testing, treatment and monitoring",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 23,
      "summary": {
        "text": "Describes maternal testing, treatment and monitoring as finding mothers through antenatal and child health services and keeping them on treatment with suppressed viral loads.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "and monitoring Identifying mothers through antenatal care and maternal, newborn and child health services, ensuring that they start ART and remain virally suppressed",
      "extractCut": false
    },
    {
      "id": "sec-014-postnatal-prophylaxis",
      "number": null,
      "title": "Postnatal prophylaxis",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 21,
      "summary": {
        "text": "Describes postnatal prophylaxis as timely antiretroviral drugs for all HIV-exposed infants, with attention to those at high risk.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Timely provision of ARV drugs to prevent HIV acquisition for all infants exposed, with particular attention to those at high risk",
      "extractCut": false
    },
    {
      "id": "sec-015-co-trimoxazole",
      "number": null,
      "title": "Co-trimoxazole",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 18,
      "summary": {
        "text": "Describes co-trimoxazole provision to prevent Pneumocystis pneumonia and deaths among infants and children living with HIV.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Timely provision of co-trimoxazole to prevent Pneumocystis jirovecii pneumonia and mortality among infants and children living with HIV",
      "extractCut": false
    },
    {
      "id": "sec-016-nurturing-care",
      "number": null,
      "title": "Nurturing care",
      "level": 3,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "4",
      "labelEnd": "6",
      "words": 456,
      "summary": {
        "text": "Describes nurturing care as simple interventions to promote early childhood development, and explains in a box that infants confirmed to have HIV should stop prophylaxis and start ART. A figure outlines components such as responsive caregiving, early learning, nutrition and maternal mental health.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nurturing care",
          "heading": true
        },
        {
          "term": "responsive caregiving",
          "heading": false
        },
        {
          "term": "integrated caregiving",
          "heading": false
        },
        {
          "term": "art regimen",
          "heading": false
        },
        {
          "term": "at-risk period",
          "heading": false
        },
        {
          "term": "maternal mental",
          "heading": false
        },
        {
          "term": "nutrition interventions",
          "heading": false
        },
        {
          "term": "postnatal prophylaxis",
          "heading": false
        }
      ],
      "extract": "Implementing simple interventions to promote early childhood development at the facility and in the community Box 1. Infants and young children living with HIV If an infant or young child is confirmed to be living with HIV during the period of follow- up, the early infant diagnosis cascade will have reached a final endpoint. If the infant is still on ARV drug prophylaxis, this should be stopped, and ART initiated",
      "extractCut": true
    },
    {
      "id": "sec-017-pnp",
      "number": null,
      "title": "PNP",
      "level": 3,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-018-nc",
      "number": null,
      "title": "NC",
      "level": 3,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-019-ctx",
      "number": null,
      "title": "CTX",
      "level": 3,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-020-hiv-positive-diagnosis",
      "number": null,
      "title": "HIV-POSITIVE DIAGNOSIS",
      "level": 3,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 6,
      "summary": {
        "text": "A fragment of a figure showing the timeline after an HIV-positive diagnosis, with a five-year age marker.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "HIV-POSITIVE DIAGNOSIS 5 years of age",
      "extractCut": false
    },
    {
      "id": "sec-021-art",
      "number": null,
      "title": "ART",
      "level": 4,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 36,
      "summary": {
        "text": "A fragment of a figure on care timelines, indicating ART for all infants and children for life and co-trimoxazole use by age and malaria or bacterial infection setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reassessment",
          "heading": false
        },
        {
          "term": "adulthood",
          "heading": false
        },
        {
          "term": "lifelong",
          "heading": false
        }
      ],
      "extract": "All infants and children regardless of clinical or immune conditions All children in settings with a high prevalence of malaria and severe bacterial infections 8 years of age 3 years of age Reassessment in adulthood Lifelong",
      "extractCut": false
    },
    {
      "id": "sec-022-routine",
      "number": null,
      "title": "Routine",
      "level": 4,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 289,
      "summary": {
        "text": "Explains the figure's key and when co-trimoxazole may stop, then describes how maternal viraemia during pregnancy and breastfeeding drives vertical HIV transmission. It lists measures to reduce this risk, including treatment adherence and continuity of care for mothers and infants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "breastfeeding period",
          "heading": false
        },
        {
          "term": "load suppression",
          "heading": false
        },
        {
          "term": "maternal viral",
          "heading": false
        },
        {
          "term": "hiv during",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        }
      ],
      "extract": "2 years of age May be discontinued if on ART, stable and viral load suppression in low-prevalence malaria and severe bacterial infection settings ID: Infant diagnosis; CTX: Co-trimoxazole; PNP: postnatal prophylaxis; NC: Nurturing care; N: Nucleic acid test; S: Serology test Maternal viraemia during pregnancy and the breastfeeding period significantly increases the risk of vertical HIV transmission (23,24). Evidence",
      "extractCut": true
    },
    {
      "id": "sec-023-1-maternal-hiv-testing-treatment-and-monitoring",
      "number": "1",
      "title": "\u0007MATERNAL HIV TESTING, TREATMENT AND MONITORING",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 11,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 82,
      "summary": {
        "text": "A chart of infants acquiring HIV through vertical transmission globally in 2020 by cause, such as mothers infected during pregnancy or breastfeeding, not on ART, stopping treatment or not virally suppressed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "mother",
          "heading": false
        }
      ],
      "extract": "AND MONITORING Fig. 4. Infants acquiring HIV vertically by cause of transmission, global, 2020 Source: UNAIDS epidemiological estimates, 2021 (1). Mother acquired HIV during pregnancy of breastfeeding Mother did not receive antiretroviral therapy during pregnancy or breastfeeding Mother did not continue with treatment during pregnancy or breastfeeding Mother was on antiretroviral therapy but not virally suppressed",
      "extractCut": true
    },
    {
      "id": "sec-024-11-maternal-hiv-testing-and-retesting",
      "number": "1.1",
      "title": "Maternal HIV testing and retesting",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 159,
      "summary": {
        "text": "Stresses early HIV testing in pregnancy with same-day ART for women who test positive, and retesting and partner testing for those at risk. It recommends third-trimester retesting for women of unknown or HIV-negative status in high-burden settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "retesting",
          "heading": true
        },
        {
          "term": "women",
          "heading": false
        },
        {
          "term": "breastfeeding",
          "heading": false
        }
      ],
      "extract": "Preventing unplanned pregnancy and HIV acquisition, confirming HIV status before pregnancy, early identification of HIV infection during pregnancy and breastfeeding and timely initiation of ART are critical for minimizing vertical HIV transmission. All pregnant women should be offered HIV testing at the earliest opportunity during pregnancy and, if HIV positive, same- day initiation of ART. HIV re-testing and",
      "extractCut": true
    },
    {
      "id": "sec-025-settings-with-a-high-burden-of-hiv-infection",
      "number": null,
      "title": "Settings with a high burden of HIV infection",
      "level": 3,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 184,
      "summary": {
        "text": "Describes HIV retesting in high-burden settings and risk-based retesting in low-burden settings, including an optional postpartum retest for women at elevated risk. It notes that suggested timings coincide with health service contacts and should prioritize high-incidence areas and key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv infection",
          "heading": true
        },
        {
          "term": "additional postpartum",
          "heading": false
        },
        {
          "term": "hiv-negative status",
          "heading": false
        },
        {
          "term": "retest",
          "heading": false
        },
        {
          "term": "burden",
          "heading": true
        },
        {
          "term": "retesting",
          "heading": false
        }
      ],
      "extract": "settings, retesting should be based on risk, emphasizing the need for ongoing risk screening (Box 2). An additional retest at 14 weeks, six months or nine months postpartum may be considered for HIV-negative women at elevated risk of acquiring HIV in settings with a high or low burden of HIV infection. The suggested times for postpartum retesting consider the opportunity provided when the mother has contact with the",
      "extractCut": true
    },
    {
      "id": "sec-026-settings-with-a-low-burden-of-hiv-infection",
      "number": null,
      "title": "Settings with a low burden of HIV infection",
      "level": 3,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 121,
      "summary": {
        "text": "Gives the guidance for low-burden settings on retesting pregnant women at ongoing risk in late pregnancy, catch-up testing when tests are missed and optional postpartum retesting for key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral loads",
          "heading": false
        },
        {
          "term": "suppressed viral",
          "heading": false
        },
        {
          "term": "hiv-negative status",
          "heading": false
        },
        {
          "term": "retest",
          "heading": false
        }
      ],
      "extract": "Retest pregnant women with unknown or HIV-negative status who are in serodiscordant relationships, whose partner does not have suppressed viral loads on ART or who have other known ongoing HIV risk in late pregnancy – at a third-trimester visit. If either the first test or retest is missed or delayed, catch-up testing is needed. An additional postpartum retest for women of unknown or HIV-negative status can be",
      "extractCut": true
    },
    {
      "id": "sec-027-implementation-considerations",
      "number": null,
      "title": "Implementation considerations",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 341,
      "summary": {
        "text": "Lists strategies to identify maternal HIV earlier by promoting early and complete antenatal care and facility births, including woman-held case notes and midwife-led continuity of care. It suggests high-prevalence countries consider routine postnatal retesting for all women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antenatal care",
          "heading": false
        },
        {
          "term": "antenatal services",
          "heading": false
        },
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "retesting",
          "heading": false
        },
        {
          "term": "targeted",
          "heading": false
        }
      ],
      "extract": "Strategies to improve early identification of maternal HIV infection should include activities that promote early initiation of antenatal services, attending all recommended antenatal visits and promoting facility deliveries. Health system interventions to improve the utilization and quality of antenatal care include: • \u0007woman-held case notes to improve the continuity and quality of care and pregnancy experience; •",
      "extractCut": true
    },
    {
      "id": "sec-028-time-points",
      "number": null,
      "title": "Time points",
      "level": 3,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 141,
      "summary": {
        "text": "A table of recommended times for HIV retesting of pregnant and postpartum women in different settings, from the first antenatal visit to the third trimester and postpartum.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ongoing risk",
          "heading": false
        },
        {
          "term": "hiv burden",
          "heading": false
        },
        {
          "term": "postpartum",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "antenatal care",
          "heading": false
        }
      ],
      "extract": "retesting should be based on local context. Table 1. Recommended times for HIV retesting for pregnant and postpartum women Source: WHO consolidated guidelines on HIV testing services, 2019 (29). Further guidance on HIV testing during pregnancy and postpartum is available (2). Time points Setting Early in pregnancy (first antenatal care visit) Late in pregnancy (third-trimester antenatal care visit) One additional",
      "extractCut": true
    },
    {
      "id": "sec-029-12-viral-load-monitoring",
      "number": "1.2",
      "title": "Viral load monitoring",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 221,
      "summary": {
        "text": "Recommends viral load monitoring during pregnancy and breastfeeding to identify women who need help achieving viral suppression, and summarizes WHO's routine monitoring schedule. It introduces a table on monitoring treatment for pregnant and breastfeeding women.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral load",
          "heading": true
        },
        {
          "term": "load monitoring",
          "heading": true
        },
        {
          "term": "unsuppressed viral",
          "heading": false
        },
        {
          "term": "viral suppression",
          "heading": false
        },
        {
          "term": "art regimen",
          "heading": false
        },
        {
          "term": "routine viral",
          "heading": false
        },
        {
          "term": "enhanced adherence",
          "heading": false
        },
        {
          "term": "breastfeeding period",
          "heading": false
        }
      ],
      "extract": "Viral load monitoring during pregnancy and the breastfeeding period is recommended to identify women who already have suppressed viral loads and to offer timely intervention to achieve viral suppression in women who are viraemic during the period of HIV transmission risk. The 2021 WHO consolidated guidelines (2) recommend routine viral load monitoring at six and 12 months after initiating ART and every 12 months",
      "extractCut": true
    },
    {
      "id": "sec-030-category",
      "number": null,
      "title": "Category",
      "level": 3,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-031-timing-of-viral-load-monitoring",
      "number": null,
      "title": "Timing of viral load monitoring",
      "level": 3,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-032-action",
      "number": null,
      "title": "Action",
      "level": 3,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 189,
      "summary": {
        "text": "A table of actions for viral load testing in pregnant women, depending on whether they started ART before or during pregnancy, including following the monitoring algorithm and considering infant testing at birth.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "load copies",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "starting art",
          "heading": false
        },
        {
          "term": "monitoring algorithm",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "enhanced postnatal",
          "heading": false
        },
        {
          "term": "postnatal prophylaxis",
          "heading": false
        }
      ],
      "extract": "Pregnant women receiving ART before conception First antenatal care visit (or when first presenting) • \u0007If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig.5) and consider infant nucleic acid testing at birth if available Pregnant women starting ART during pregnancy Three months after initiating ART • \u0007If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig. 5) •",
      "extractCut": true
    },
    {
      "id": "sec-033-point-of-care-viral-load-testing",
      "number": null,
      "title": "Point-of-care viral load testing",
      "level": 3,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 317,
      "summary": {
        "text": "Sets out evidence that point-of-care viral load testing improves access, speeds results and helps continuity of treatment, and recommends prioritizing it for pregnant and breastfeeding women. It lists requirements such as quality assurance, supply chains and maintenance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care viral",
          "heading": true
        },
        {
          "term": "viral load",
          "heading": true
        },
        {
          "term": "load testing",
          "heading": true
        },
        {
          "term": "load technologies",
          "heading": false
        },
        {
          "term": "breastfeeding mothers",
          "heading": false
        },
        {
          "term": "turnaround time",
          "heading": false
        },
        {
          "term": "placement",
          "heading": false
        },
        {
          "term": "network",
          "heading": false
        }
      ],
      "extract": "Evidence suggests that point-of-care viral load testing has the capacity to improve access to viral load testing, reduce turnaround time for results to the clinician, increase the probability of same-day results, improve the timeliness of clinical action to address elevated viral load and increase continuity of treatment and viral suppression (30–32). Point-of-care testing should be considered especially for",
      "extractCut": true
    },
    {
      "id": "sec-034-implementation-considerations",
      "number": null,
      "title": "Implementation considerations",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 410,
      "summary": {
        "text": "Recommends expanding viral load testing through laboratory capacity, sample transport, dried blood spot collection and point-of-care networks. It then describes the early infant diagnosis schedule, including testing at six weeks, after breastfeeding exposure and serology at 18 months.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "load testing",
          "heading": false
        },
        {
          "term": "point-of-care viral",
          "heading": false
        },
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "acid testing",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "months",
          "heading": false
        }
      ],
      "extract": "Viral load testing capacity and coverage should be expanded by scaling up laboratory viral load testing infrastructure; strengthening the efficiency of sample processing and transport systems; supporting community viral load sample collection and testing using dried blood spot or plasma separation card and establishing networks for point-of-care viral load testing to improve access on the maternal; newborn and child",
      "extractCut": true
    },
    {
      "id": "sec-035-early-infant-diagnosis-for-high-risk-infants",
      "number": null,
      "title": "Early infant diagnosis for high-risk infants",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 67,
      "summary": {
        "text": "Suggests that high-risk infants may be offered nucleic acid testing at birth, and that infants first found to be exposed after delivery should be tested and started on presumptive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infants",
          "heading": true
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "acid testing",
          "heading": false
        }
      ],
      "extract": "Nucleic acid testing at birth may be considered for high- risk infants. In addition, infants who are first identified as HIV-exposed postpartum have a high cumulative risk of already having acquired HIV by the time prophylaxis is initiated. Under these circumstances, HIV nucleic acid testing should be performed and presumptive treatment started to avoid extended prophylaxis among infants who are already HIV infected",
      "extractCut": true
    },
    {
      "id": "sec-036-point-of-care-infant-diagnosis",
      "number": null,
      "title": "Point-of-care infant diagnosis",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 294,
      "summary": {
        "text": "Reports that only 60% of HIV-exposed infants were tested by two months of age in 2020, with delays in results and linkage to treatment. It describes evidence that point-of-care nucleic acid testing speeds results and treatment and calls for systematic follow-up of mother–baby pairs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "point-of-care infant",
          "heading": true
        },
        {
          "term": "infant diagnosis",
          "heading": true
        },
        {
          "term": "infant testing",
          "heading": false
        },
        {
          "term": "diagnosis cascade",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "continuity along",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "tested",
          "heading": false
        }
      ],
      "extract": "Access to early infant diagnosis remains low, with only 60% of infants exposed to HIV globally tested by the second month of age in 2020 (39). Even when infants are tested, delays in receiving test results and weak linkage to ART contribute to attrition along the testing- to-treatment cascade. Evidence suggests that point-of- care nucleic acid testing enables more rapid testing with return of results to caregivers",
      "extractCut": true
    },
    {
      "id": "sec-037-2-infant-diagnosis",
      "number": "2",
      "title": "\u0007INFANT DIAGNOSIS",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 17,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 296,
      "summary": {
        "text": "Presents WHO's strong recommendation to use point-of-care nucleic acid testing to diagnose HIV in children under 18 months, with guidance on placing these technologies. It also covers infant feeding, noting that mothers on ART with suppressed viral loads can breastfeed up to two years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infant diagnosis",
          "heading": true
        },
        {
          "term": "point-of-care infant",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "acid testing",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "breastfeeding",
          "heading": false
        },
        {
          "term": "networks",
          "heading": false
        },
        {
          "term": "recommendation",
          "heading": false
        }
      ],
      "extract": "Box 4. WHO recommendation on point-of- care infant diagnosis Point-of-care nucleic acid testing should be used to diagnose HIV among infants and children younger than 18 months of age (strong recommendation; high-certainty evidence). Source: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update (2). Point-of-care",
      "extractCut": true
    },
    {
      "id": "sec-038-3-infant-antiretroviral-prophylaxis",
      "number": "3",
      "title": "INFANT ANTIRETROVIRAL PROPHYLAXIS",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 94,
      "summary": {
        "text": "Presents a WHO good practice statement that ART should start before or urgently during pregnancy and breastfeeding, since suppressing maternal viral load is the most effective way to prevent vertical transmission.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prophylaxis",
          "heading": true
        },
        {
          "term": "suppress",
          "heading": false
        },
        {
          "term": "pregnancy",
          "heading": false
        }
      ],
      "extract": "Box 5. WHO good practice statement ART should be initiated before pregnancy and urgently among all pregnant and breastfeeding women living with HIV, even if they are identified late in pregnancy or postpartum, because the most effective way to reduce the risk of HIV vertical transmission is to suppress maternal viral load. Whenever possible, all efforts should be made to identify HIV-infected pregnant women early",
      "extractCut": true
    },
    {
      "id": "sec-039-risk-assessment-of-infants-exposed-to-hiv",
      "number": null,
      "title": "Risk assessment of infants exposed to HIV",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 195,
      "summary": {
        "text": "Explains how HIV-exposed infants are assessed as low or high risk of vertical transmission based on maternal treatment and viral load. Infants are low risk when mothers are on ART with suppressed viral loads, and WHO's definition of high-risk infants is given.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infants exposed",
          "heading": true
        },
        {
          "term": "risk assessment",
          "heading": true
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "established hiv",
          "heading": false
        }
      ],
      "extract": "Risk assessment is based on prevailing maternal factors that affect the probability of HIV vertical transmission and is essential for selecting appropriate preventive interventions for infants exposed to HIV. Infants exposed to HIV are considered to have low risk for vertical transmission if their mothers are receiving ART and have suppressed viral loads during pregnancy and delivery and throughout breastfeeding.",
      "extractCut": true
    },
    {
      "id": "sec-040-antiretroviral-prophylaxis",
      "number": null,
      "title": "Antiretroviral prophylaxis",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 21,
      "summary": {
        "text": "States that a single antiretroviral drug for four to six weeks is recommended as postnatal prophylaxis for infants at low risk of vertical transmission.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Infants at low risk of vertical transmission should receive a single ARV drug as postnatal prophylaxis for 4–6 weeks (Box 6).",
      "extractCut": false
    },
    {
      "id": "sec-041-enhanced-postnatal-prophylaxis",
      "number": null,
      "title": "Enhanced postnatal prophylaxis",
      "level": 3,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 332,
      "summary": {
        "text": "Describes enhanced postnatal prophylaxis for high-risk infants using dual antiretroviral drugs for six weeks followed by six more weeks of dual or single drugs, with alternative regimens if needed. It gives the related WHO recommendation and its certainty of evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prophylaxis",
          "heading": true
        },
        {
          "term": "six weeks",
          "heading": false
        },
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "arv drugs",
          "heading": false
        },
        {
          "term": "nvp",
          "heading": false
        },
        {
          "term": "hiv mother",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        }
      ],
      "extract": "Infants at high risk for vertical transmission should receive dual ARV drugs for six weeks followed by dual or single ARV drugs for another six weeks for a total of 12 weeks (Box 6). When the recommended regimen is not available or feasible, alternative options such as RAL, 3TC, LPV/r solid formulations or triple-drug fixed-dose combinations containing AZT, NVP and 3TC may be considered (see Annex 1 for the dosing",
      "extractCut": true
    },
    {
      "id": "sec-042-implementation-considerations",
      "number": null,
      "title": "Implementation considerations",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 213,
      "summary": {
        "text": "Reports how 18 priority countries have adopted enhanced postnatal prophylaxis, some for all breastfeeding HIV-exposed infants and others only for high-risk infants. It advises providing infant prophylaxis in the same setting as maternal ART.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "postnatal prophylaxis",
          "heading": false
        },
        {
          "term": "enhanced postnatal",
          "heading": false
        },
        {
          "term": "adopted enhanced",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "breastfeeding period",
          "heading": false
        },
        {
          "term": "maternal viral",
          "heading": false
        },
        {
          "term": "countries adopted",
          "heading": false
        }
      ],
      "extract": "Various countries have adopted enhanced postnatal prophylaxis using a variety of approaches to adapt to the country context. A policy review conducted in 18 AIDS Free priority countries revealed that seven countries adopted enhanced postnatal prophylaxis for all breastfeeding infants exposed to HIV and 11 countries for only high-risk infants. Risk was determined primarily based on the timing of maternal HIV",
      "extractCut": true
    },
    {
      "id": "sec-043-providing-enhanced-postnatal-prophylaxis-to-all",
      "number": null,
      "title": "Providing enhanced postnatal prophylaxis to all infants exposed to HIV",
      "level": 3,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 105,
      "summary": {
        "text": "Describes giving enhanced prophylaxis to all HIV-exposed infants as an interim measure where maternal ART and viral suppression are poor, noting the trade-offs of cost, drug supply and unnecessary toxicity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "maternal viral",
          "heading": false
        },
        {
          "term": "poor maternal",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "viral suppression",
          "heading": false
        }
      ],
      "extract": "exposed to HIV This may be considered in settings in which most mothers are at high risk of transmitting HIV because of poor maternal ART coverage, high rates of loss to follow-up, poor maternal viral load testing coverage and poor maternal viral suppression rates. It should serve as an interim measure as strategies to improve maternal ART coverage, maternal viral load testing coverage and maternal viral suppression",
      "extractCut": true
    },
    {
      "id": "sec-044-extended-or-prolonged-postnatal-prophylaxis-beyo",
      "number": null,
      "title": "Extended or prolonged postnatal prophylaxis beyond",
      "level": 3,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 196,
      "summary": {
        "text": "Discusses extended prophylaxis beyond 12 weeks for infants still at high risk during breastfeeding, listing circumstances of persistent risk. It advises against restarting prophylaxis once stopped and favours support for maternal adherence instead.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prophylaxis",
          "heading": true
        },
        {
          "term": "maternal art",
          "heading": false
        },
        {
          "term": "maternal adherence",
          "heading": false
        },
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "prolonged",
          "heading": true
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "viral suppression",
          "heading": false
        }
      ],
      "extract": "12 weeks Although limited evidence suggests additional benefit of combination or prolonged regimens in the context of maternal ART (44), infants and young children who remain at high risk for HIV transmission during the breastfeeding period may receive extended prophylaxis until the risk is considered limited or has ended. Circumstances that present persistent risk to breastfeeding infants beyond the recommended 12",
      "extractCut": true
    },
    {
      "id": "sec-045-presumptive-treatment",
      "number": null,
      "title": "Presumptive treatment",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 213,
      "summary": {
        "text": "Describes presumptive treatment for infants identified as HIV-exposed late, whose mothers were diagnosed late or infected while breastfeeding, involving nucleic acid testing and starting treatment straight away. It notes how the regimen should be adjusted after results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "presumptive treatment",
          "heading": true
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "maternal art",
          "heading": false
        },
        {
          "term": "drug regimen",
          "heading": false
        },
        {
          "term": "arv drug",
          "heading": false
        },
        {
          "term": "hiv late",
          "heading": false
        },
        {
          "term": "drug prophylaxis",
          "heading": false
        }
      ],
      "extract": "Infants may be identified as exposed to HIV late when they present for health services outside the prevention- of-vertical-transmission cascade. Their mothers may be diagnosed with HIV late or may have acquired HIV during the breastfeeding period. These infants are at high risk of vertical transmission because of high levels of maternal viraemia and the absence of maternal ART. Under these circumstances, nucleic",
      "extractCut": true
    },
    {
      "id": "sec-046-4-co-trimoxazole-prophylaxis",
      "number": "4",
      "title": "CO-TRIMOXAZOLE PROPHYLAXIS",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 272,
      "summary": {
        "text": "Describes the history of co-trimoxazole prophylaxis in WHO guidelines since 2006, from preventing Pneumocystis pneumonia and toxoplasmosis to preventing malaria and severe bacterial infections. It presents the current recommendation for HIV-exposed infants and children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "co-trimoxazole prophylaxis",
          "heading": true
        },
        {
          "term": "infants exposed",
          "heading": false
        },
        {
          "term": "severe bacterial",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "bacterial infections",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "malaria",
          "heading": false
        }
      ],
      "extract": "Co-trimoxazole prophylaxis was first introduced in the WHO guidelines in 2006 as a component of standard HIV care, primarily as prophylaxis for Pneumocystis jirovecii pneumonia and toxoplasmosis for people living with HIV and infants exposed to HIV until it could be reliably established that they were HIV-uninfected (46). In subsequent years, the use of co-trimoxazole prophylaxis was extended to preventing malaria",
      "extractCut": true
    },
    {
      "id": "sec-047-population",
      "number": null,
      "title": "Population",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-048-criteria-for-initiating-co-trimoxazole-prophylax",
      "number": null,
      "title": "Criteria for initiating co-trimoxazole prophylaxis",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 2,
      "summary": {
        "text": "A table column heading for criteria for initiating co-trimoxazole prophylaxis.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "co-trimoxazole prophylaxis",
      "extractCut": false
    },
    {
      "id": "sec-049-criteria-for-discontinuing-co-trimoxazole-prophy",
      "number": null,
      "title": "Criteria for discontinuing co-trimoxazole prophylaxis",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 2,
      "summary": {
        "text": "A table column heading for criteria for discontinuing co-trimoxazole prophylaxis.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "co-trimoxazole prophylaxis",
      "extractCut": false
    },
    {
      "id": "sec-050-children-and-adolescents-living-with-hiv",
      "number": null,
      "title": "Children and adolescents living with HIV",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 119,
      "summary": {
        "text": "Gives criteria for starting and stopping co-trimoxazole in children and adolescents living with HIV, with priority for under-fives and those with advanced disease, and continuation in high malaria and bacterial infection settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "severe bacterial",
          "heading": false
        },
        {
          "term": "bacterial infections",
          "heading": false
        },
        {
          "term": "five years",
          "heading": false
        }
      ],
      "extract": "living with HIV • \u0007Initiate for everyone regardless of WHO clinical stage or CD4 cell count • \u0007As a priority: – \u0007Initiate for everyone younger than five years regardless of WHO clinical stage or CD4 cell count – \u0007Initiate for everyone five years and older with severe or advanced HIV disease (WHO clinical stage 3 or 4) or CD4 cell count ≤350 cells/mm3 • \u0007In settings with high prevalence of malaria and/or severe",
      "extractCut": true
    },
    {
      "id": "sec-051-hiv-exposed-infants",
      "number": null,
      "title": "HIV-exposed infants",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 35,
      "summary": {
        "text": "States that co-trimoxazole should start for all HIV-exposed infants at four to six weeks and continue until HIV is excluded, as part of a table of initiation and discontinuation criteria.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "until",
          "heading": false
        },
        {
          "term": "discontinuing",
          "heading": false
        },
        {
          "term": "age-appropriate",
          "heading": false
        }
      ],
      "extract": "Initiate for everyone starting at 4–6 weeks after birth Until the risk of HIV transmission ends and HIV infection is excluded with age-appropriate testb Table 3. Criteria for initiating and discontinuing co-trimoxazole prophylaxis among children",
      "extractCut": false
    },
    {
      "id": "sec-052-implementation-considerations",
      "number": null,
      "title": "Implementation considerations",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-053-infants-exposed-to-hiv-and-uninfected",
      "number": null,
      "title": "Infants exposed to HIV and uninfected",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 24,
      "labelStart": "19",
      "labelEnd": "21",
      "words": 1144,
      "summary": {
        "text": "Reviews evidence on co-trimoxazole for infants who are HIV-exposed but uninfected, citing trials that found no clear benefit, and discusses how policies might be applied in different settings. It then turns to health and development, noting that HIV-exposed children are more likely to have motor and cognitive delays. It introduces nurturing care, including health, nutrition, security, responsive caregiving and early learning.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "co-trimoxazole prophylaxis",
          "heading": false
        },
        {
          "term": "hiv exposed",
          "heading": true
        },
        {
          "term": "shorter co-trimoxazole",
          "heading": false
        },
        {
          "term": "co-trimoxazole group",
          "heading": false
        },
        {
          "term": "providing co-trimoxazole",
          "heading": false
        },
        {
          "term": "co-trimoxazole provision",
          "heading": false
        },
        {
          "term": "uninfected",
          "heading": true
        },
        {
          "term": "infants",
          "heading": true
        }
      ],
      "extract": "A systematic review was conducted to assess the effect of co-trimoxazole prophylaxis on the morbidity and mortality of infants who are HIV exposed and uninfected (51). Two trials were identified that addressed the research question. A randomized placebo-controlled trial in Botswana (52) that started co-trimoxazole at 14–34 days and continued it until 15 months of age showed no evidence of benefit of co-trimoxazole",
      "extractCut": true
    },
    {
      "id": "sec-054-responsive-caregiving",
      "number": null,
      "title": "Responsive caregiving",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 25,
      "summary": {
        "text": "Notes that nurturing care, including responsive caregiving and early learning, directly supports child development, with a figure of its components.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "and opportunities for early learning (Fig. 6), directly affects child development, supporting children to reach their full developmental potential. Fig. 6. Components of nurturing care",
      "extractCut": false
    },
    {
      "id": "sec-055-5-promoting-nurturing-care",
      "number": "5",
      "title": "PROMOTING NURTURING CARE",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 160,
      "summary": {
        "text": "Describes developmental assessments using standardized, validated tools to measure motor, cognitive, communication and social skills. It presents WHO's recommendation that all infants receive responsive care in their first three years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nurturing care",
          "heading": true
        },
        {
          "term": "developmental assessments",
          "heading": false
        },
        {
          "term": "responsive care",
          "heading": false
        },
        {
          "term": "caregivers",
          "heading": false
        },
        {
          "term": "comparing",
          "heading": false
        },
        {
          "term": "skills",
          "heading": false
        }
      ],
      "extract": "Developmental assessments by direct measurement and observation are used to assess various aspects of a child’s functioning and abilities (motor, sensory, cognition, communication, behaviour, social interaction and adaptive skills). Systematic and structured developmental assessments using standardized validated tools are advised. Several age-dependent tools are used for formal developmental assessment, including",
      "extractCut": true
    },
    {
      "id": "sec-056-promote-early-learning",
      "number": null,
      "title": "Promote early learning",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 43,
      "summary": {
        "text": "States WHO's strong recommendation that all young children take part in early learning activities with caregivers during the first three years, with caregivers supported to do so.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "learning",
          "heading": true
        },
        {
          "term": "caregivers",
          "heading": false
        },
        {
          "term": "parents",
          "heading": false
        }
      ],
      "extract": "All infants and children should have early learning activities with their parents and other caregivers during the first three years of life; parents and other caregivers should be supported to engage in early learning with their infants and children (strong recommendation; moderate-quality evidence).",
      "extractCut": false
    },
    {
      "id": "sec-057-integrate-caregiving-and-nutrition-interventions",
      "number": null,
      "title": "Integrate caregiving and nutrition interventions",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 26,
      "summary": {
        "text": "States WHO's recommendation to include support for responsive care and early learning in infant and young child nutrition interventions.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Support for responsive care and early learning should be included as part of interventions for optimal nutrition of infants and young children (strong recommendation; moderate-quality evidence).",
      "extractCut": false
    },
    {
      "id": "sec-058-support-maternal-mental-health",
      "number": null,
      "title": "Support maternal mental health",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 27,
      "summary": {
        "text": "States WHO's recommendation to integrate psychosocial support for maternal mental health into early childhood health and development services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mental",
          "heading": true
        },
        {
          "term": "maternal",
          "heading": true
        },
        {
          "term": "childhood",
          "heading": false
        }
      ],
      "extract": "Psychosocial interventions to support maternal mental health should be integrated into early childhood health and development services (strong recommendation; moderate-quality evidence). Source: Improving early childhood development (60).",
      "extractCut": false
    },
    {
      "id": "sec-059-implementation-considerations",
      "number": null,
      "title": "Implementation considerations",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "21",
      "labelEnd": "22",
      "words": 106,
      "summary": {
        "text": "Calls for multistakeholder and multisectoral approaches to nurturing care, locally validated developmental screening tools and referral systems for infants exposed to HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "implement nurturing",
          "heading": false
        },
        {
          "term": "nurturing care",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "implementation",
          "heading": true
        }
      ],
      "extract": "Multistakeholder engagement and multisectoral approaches at the national and community levels to ensure local contexts and available supportive systems to implement nurturing care interventions are considered critical to comprehensive service delivery, uptake and sustainability. Programmes should select validated tools that are appropriate for implementation in the local context to identify infants and young",
      "extractCut": true
    },
    {
      "id": "sec-060-policy-implementation-considerations-for-the-com",
      "number": null,
      "title": "POLICY IMPLEMENTATION CONSIDERATIONS FOR THE COMPREHENSIVE PACKAGE OF CARE",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 34,
      "summary": {
        "text": "Advises countries to adapt the comprehensive package of care to their capacity while still delivering all components together.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "to their specific contexts based on the level of implementation and capacities for the individual components, nevertheless endeavouring to ensure that all the components of care are optimally delivered jointly in a comprehensive approach.",
      "extractCut": false
    },
    {
      "id": "sec-061-national-level",
      "number": null,
      "title": "National level",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 87,
      "summary": {
        "text": "Recommends placing the package of care for HIV-exposed infants on reproductive, maternal, newborn, child and adolescent health platforms, aligned with related policies and backed by commodities, funding and coordination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adolescent health",
          "heading": false
        },
        {
          "term": "package",
          "heading": false
        },
        {
          "term": "newborn",
          "heading": false
        }
      ],
      "extract": "The comprehensive integrated package of care for infants and young children exposed to HIV should be strategically positioned on reproductive, maternal, newborn, child and adolescent health platforms. Contextual assessment and inclusive multistakeholder engagement for operationalizing this package of care will be critical. It will be important for programme leadership to ensure that the care package is aligned with",
      "extractCut": true
    },
    {
      "id": "sec-062-human-resources",
      "number": null,
      "title": "Human resources",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 50,
      "summary": {
        "text": "Notes that introducing the care package for HIV-exposed infants must account for limited staff capacity, and that lay and peer providers and community health workers offer scope for task sharing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "human",
          "heading": true
        },
        {
          "term": "resources",
          "heading": true
        },
        {
          "term": "lay",
          "heading": false
        }
      ],
      "extract": "The potential challenges of introducing a new care package within contexts of limited human resources and capacity at the different levels of care need to be carefully considered. Existing networks, including lay and peer providers and community health workers at facilities and in communities, provide opportunities for task sharing and",
      "extractCut": false
    },
    {
      "id": "sec-063-service-delivery",
      "number": null,
      "title": "Service delivery",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "22",
      "labelEnd": "23",
      "words": 680,
      "summary": {
        "text": "Continues the human resources point, listing tasks such as psychosocial and adherence support, sample transport and drug distribution that could be shared, with capacity building and innovative tools. It then describes service delivery, recommending integration of the care package into reproductive, maternal, newborn and child health platforms, with standard procedures and synchronized appointments for mother–infant pairs. It also calls for community-based strategies to keep exposed infants in care through to final diagnosis and to maintain services during disasters and pandemics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "service delivery",
          "heading": true
        },
        {
          "term": "young mothers",
          "heading": false
        },
        {
          "term": "young children",
          "heading": false
        },
        {
          "term": "children exposed",
          "heading": false
        },
        {
          "term": "care package",
          "heading": false
        },
        {
          "term": "comprehensive package",
          "heading": false
        },
        {
          "term": "preventing vertical",
          "heading": false
        },
        {
          "term": "vertical transmission",
          "heading": false
        }
      ],
      "extract": "including psychosocial and adherence support, community follow-up, sample collection, sample transport and drug distribution. This will entail capacity building for the cadres engaged in the various components of the care package and, if possible, innovative technologies, tools and aids to facilitate its implementation. Service delivery The comprehensive care package should be strategically integrated on",
      "extractCut": true
    },
    {
      "id": "sec-064-monitoring-evaluation-and-learning",
      "number": null,
      "title": "Monitoring, evaluation and learning",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 367,
      "summary": {
        "text": "Lists monitoring priorities for the care package for HIV-exposed infants, from antenatal and postnatal attendance and maternal ART and viral suppression to early infant diagnosis coverage and follow-up to final diagnosis. It also calls for implementation research to guide phased roll-out and for adequate funding and training of monitoring and evaluation staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "maternal art",
          "heading": false
        },
        {
          "term": "maternal viral",
          "heading": false
        },
        {
          "term": "hiv disaggregated",
          "heading": false
        },
        {
          "term": "evaluation systems",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "infant diagnosis",
          "heading": false
        },
        {
          "term": "existing reproductive",
          "heading": false
        },
        {
          "term": "linked services",
          "heading": false
        }
      ],
      "extract": "Determining priorities for monitoring and evaluating the comprehensive package of care and identifying programme indicators are important for programmes. Priorities for monitoring will include: • antenatal initiation and attendance; • postnatal attendance; • \u0007the number of pregnant and breastfeeding women living with HIV disaggregated for timing of HIV diagnosis, maternal ART coverage, maternal ART timing, maternal",
      "extractCut": true
    },
    {
      "id": "sec-065-quality-improvement",
      "number": null,
      "title": "Quality improvement",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 125,
      "summary": {
        "text": "Describes using quality improvement methods, quality indicators and client-led initiatives involving mothers to close gaps in care for HIV-exposed infants, particularly in decentralized, resource-limited settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "quality improvement",
          "heading": true
        },
        {
          "term": "address gaps",
          "heading": false
        },
        {
          "term": "package",
          "heading": false
        },
        {
          "term": "patient-centred",
          "heading": false
        }
      ],
      "extract": "To ensure a safe, effective, patient-centred comprehensive package of care for infants and young children who are HIV exposed, quality improvement can be used to address gaps along the continuum of care. Quality can be assessed to ensure that the standards of care are met and to minimize missed opportunities. Key to this will be identifying quality indicators. Quality improvement teams and/or health-care providers",
      "extractCut": true
    },
    {
      "id": "sec-066-research-gaps",
      "number": null,
      "title": "Research gaps",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-067-arv-drug-prophylaxis",
      "number": null,
      "title": "ARV drug prophylaxis",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 166,
      "summary": {
        "text": "Identifies research gaps on antiretroviral prophylaxis for HIV-exposed infants, including the added value of combination or prolonged prophylaxis and prophylaxis when exposure is identified late or the mother acquires HIV after pregnancy begins. It also calls for better infant drug formulations and studies on maternal viraemia during breastfeeding and on defining high-risk infants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prophylaxis",
          "heading": true
        },
        {
          "term": "infant prophylaxis",
          "heading": false
        },
        {
          "term": "postpartum period",
          "heading": false
        },
        {
          "term": "maternal art",
          "heading": false
        },
        {
          "term": "additional benefit",
          "heading": false
        },
        {
          "term": "arv",
          "heading": true
        }
      ],
      "extract": "The additional benefit of combination or prolonged infant prophylaxis with maternal ART remains uncertain. In addition, limited evidence supports infant prophylaxis for infants with HIV exposure identified during the postpartum period or the mother acquiring HIV during pregnancy and the breastfeeding period. Research is needed, including clinical and pharmacological studies, to inform the development of improved ARV",
      "extractCut": true
    },
    {
      "id": "sec-068-co-trimoxazole-prophylaxis",
      "number": null,
      "title": "Co-trimoxazole prophylaxis",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 159,
      "summary": {
        "text": "States that WHO expects to fully review its co-trimoxazole prophylaxis recommendation for HIV-exposed infants as evidence accumulates. It lists research questions such as optimal start timing, shorter duration, alternative antibiotics, antimicrobial resistance and effects on the microbiome.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "co-trimoxazole prophylaxis",
          "heading": true
        },
        {
          "term": "clinical relevance",
          "heading": false
        },
        {
          "term": "antibiotic",
          "heading": false
        },
        {
          "term": "shorter",
          "heading": false
        },
        {
          "term": "anticipates",
          "heading": false
        }
      ],
      "extract": "WHO anticipates fully reviewing the co-trimoxazole prophylaxis recommendation as further evidence is gathered and increasing progress is made, to rapidly identify infants living with HIV and retaining those exposed to HIV in the testing cascade until final diagnosis is ascertained. Research gaps remain about how to optimize the use of co-trimoxazole prophylaxis, and well-conducted operational research will be",
      "extractCut": true
    },
    {
      "id": "sec-069-other-gaps",
      "number": null,
      "title": "Other gaps",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "24",
      "labelEnd": "25",
      "words": 58,
      "summary": {
        "text": "Notes further research needs on integrating nurturing care and caregiver support into services for HIV-exposed infants and on the impact of HIV services integrated into routine child health care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nurturing",
          "heading": false
        },
        {
          "term": "caregiver",
          "heading": false
        },
        {
          "term": "integrated",
          "heading": false
        }
      ],
      "extract": "The impact of integrating nurturing care interventions into service delivery for infants and young children exposed to HIV needs to be better understood. The impact of caregiver support interventions may also need to be further explored. Finally, more research on integrated services is needed, especially to document the impact of HIV services when integrated into routine child services.",
      "extractCut": false
    },
    {
      "id": "sec-070-references",
      "number": null,
      "title": "REFERENCES",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 31,
      "labelStart": "25",
      "labelEnd": "28",
      "words": 2020,
      "summary": {
        "text": "The reference list for the guidance on care of HIV-exposed infants and young children, citing UNAIDS estimates, WHO consolidated HIV guidelines and studies on outcomes, prophylaxis and child development.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uninfected infants",
          "heading": false
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "uninfected children",
          "heading": false
        },
        {
          "term": "co-trimoxazole prophylaxis",
          "heading": false
        },
        {
          "term": "cotrimoxazole prophylaxis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "defic syndr",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        }
      ],
      "extract": "1. \u0007UNAIDS epidemiological estimates [online database]. Geneva: UNAIDS; 2021 (https://aidsinfo.unaids.org, accessed 27 September 2021). 2. \u0007Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 update (https://apps.who.int/iris/ handle/10665/342899, accessed 27 September 2021).",
      "extractCut": true
    },
    {
      "id": "sec-071-annex-1-simplified-age-based-antiretroviral-drug",
      "number": "Annex 1",
      "title": "\u0007SIMPLIFIED AGE-BASED ANTIRETROVIRAL DRUG DOSING FOR ADMINISTERING ENHANCED AND PROLONGED POSTNATAL PROPHYLAXIS",
      "level": 1,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "28",
      "labelEnd": "29",
      "words": 359,
      "summary": {
        "text": "An annex table giving simplified age-based dosing of nevirapine and zidovudine for enhanced and prolonged postnatal prophylaxis in HIV-exposed infants. Its notes describe alternative drugs, such as raltegravir, lamivudine or lopinavir/ritonavir, for use during stock-outs, and it is sourced from the 2021 WHO consolidated HIV guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dosing",
          "heading": true
        },
        {
          "term": "neonates weighing",
          "heading": false
        },
        {
          "term": "infants weighing",
          "heading": false
        },
        {
          "term": "weight band",
          "heading": false
        },
        {
          "term": "nvp",
          "heading": false
        },
        {
          "term": "tablets",
          "heading": false
        },
        {
          "term": "azt",
          "heading": false
        }
      ],
      "extract": "ANTIRETROVIRAL DRUG DOSING FOR ADMINISTERING ENHANCED AND PROLONGED POSTNATAL PROPHYLAXIS a a \u0007In special circumstances with stock-outs of NVP and/or AZT, alternative ARV drugs could be used: RAL with treatment dosing, 3TC or LPV/r based on evidence gathered through the PROMISE trial (3TC was administered as follows: 7.5 mg once daily for neonates weighing 2 to <4 kg, 25 mg once daily for infants weighing 4 to <8 kg",
      "extractCut": true
    },
    {
      "id": "sec-072-annex-2-simplified-dosing-of-co--trimoxazole-pro",
      "number": "Annex 2",
      "title": "\u0007SIMPLIFIED DOSING OF CO- TRIMOXAZOLE PROPHYLAXIS FOR INFANTS AND CHILDREN AT LEAST FOUR WEEKS OLD",
      "level": 1,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "29",
      "labelEnd": "30",
      "words": 11,
      "summary": {
        "text": "The heading of an annex table on simplified co-trimoxazole prophylaxis dosing for infants and children aged four weeks or older; the table itself was not extracted.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "TRIMOXAZOLE PROPHYLAXIS FOR INFANTS AND CHILDREN AT LEAST FOUR WEEKS OLD",
      "extractCut": false
    },
    {
      "id": "sec-073-annex-3-infant-diagnosis-algorithm",
      "number": null,
      "title": "\u0007ANNEX 3. INFANT DIAGNOSIS ALGORITHM",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 34,
      "labelStart": "30",
      "labelEnd": "31",
      "words": 431,
      "summary": {
        "text": "Annex 3, the infant HIV diagnosis algorithm from the 2021 WHO consolidated guidelines, with notes on optional birth testing, point-of-care nucleic acid testing, starting ART immediately while confirming a positive result and the rising risk of false positives. It shows testing at set ages through to final diagnosis at 18 months or three months after breastfeeding ends.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "repeat nat",
          "heading": false
        },
        {
          "term": "infant",
          "heading": true
        },
        {
          "term": "confirm infection",
          "heading": false
        },
        {
          "term": "antibody testing",
          "heading": false
        },
        {
          "term": "infant child",
          "heading": false
        },
        {
          "term": "start artc",
          "heading": false
        },
        {
          "term": "conduct natb",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        }
      ],
      "extract": "Source: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 update (https://apps.who.int/iris/handle/10665/342899, accessed 27 September 2021). Notes: a. Based on 2016 WHO Consolidated ARV Guidelines, addition of NAT at birth to the existing testing algorithm can be",
      "extractCut": true
    },
    {
      "id": "sec-074-for-more-information-contact",
      "number": null,
      "title": "For more information, contact:",
      "level": 2,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 21,
      "summary": {
        "text": "The contact details of the WHO Department of Global HIV, Hepatitis and STIs Programmes in Geneva.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "World Health Organization Department of Global HIV, Hepatitis and STIs Programmes World Health Organization 20, avenue Appia 1211 Geneva 27 Switzerland",
      "extractCut": false
    },
    {
      "id": "sec-075-e-mail-hiv-aidswhoint-wwwwhointhiv",
      "number": null,
      "title": "E-mail: hiv-aids@who.int www.who.int/hiv",
      "level": 2,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 28,
      "summary": {
        "text": "The back-cover details with WHO HIV contact information, electronic and print ISBNs and the CC BY-NC-SA 3.0 IGO licence, dated 2021.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "int",
          "heading": true
        },
        {
          "term": "www",
          "heading": true
        },
        {
          "term": "isbn",
          "heading": false
        }
      ],
      "extract": "www.who.int/hiv ISBN 978-92-4-004023-6 (electronic version) ISBN 978-92-4-004024-3 (print version) © World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.",
      "extractCut": false
    }
  ],
  "checks": {
    "figureSequenceGaps": [
      "figure 2",
      "figure 3"
    ],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "breastfeeding infants",
      "heading": true
    },
    {
      "term": "hiv infant",
      "heading": false
    },
    {
      "term": "maternal hiv",
      "heading": true
    },
    {
      "term": "infants exposed",
      "heading": true
    },
    {
      "term": "hiv testing",
      "heading": true
    },
    {
      "term": "infant prophylaxis",
      "heading": true
    },
    {
      "term": "hiv vertical",
      "heading": false
    },
    {
      "term": "hiv transmission",
      "heading": true
    },
    {
      "term": "maternal art",
      "heading": false
    },
    {
      "term": "hiv during",
      "heading": false
    },
    {
      "term": "infants living",
      "heading": true
    },
    {
      "term": "co-trimoxazole prophylaxis",
      "heading": true
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "1",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "3",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 5,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "31",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Components of the comprehensive package of care for infants and young children exposed to HIV",
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Infants and young children living with",
      "page": 7,
      "pageLabel": "4",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "4",
      "title": "Infants acquiring HIV vertically by cause of transmission, global, 2020",
      "page": 10,
      "pageLabel": "7",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "Suggested optimal retesting frequency for pregnant and breastfeeding women Settings with a high burden of HIV infection",
      "page": 11,
      "pageLabel": "8",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Recommended times for HIV retesting for pregnant and postpartum women",
      "page": 12,
      "pageLabel": "9",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Monitoring treatment for pregnant and breastfeeding women",
      "page": 13,
      "pageLabel": "10",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "3",
      "title": "WHO recommendations on point-of-",
      "page": 14,
      "pageLabel": "11",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "4",
      "title": "WHO recommendation on point-of-",
      "page": 15,
      "pageLabel": "12",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "5",
      "title": "WHO good practice statement",
      "page": 17,
      "pageLabel": "14",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "5",
      "title": "Algorithm for risk assessment at the time of delivery to help identify infants at high and low risk of infection",
      "page": 18,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "6",
      "title": "WHO recommendations on infant ARV prophylaxis Infants of mothers who are receiving ART and are breastfeeding should receive six weeks of infant prophylaxis with",
      "page": 19,
      "pageLabel": "16",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Criteria for initiating and discontinuing co-trimoxazole prophylaxis among children",
      "page": 21,
      "pageLabel": "18",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "\u0007Summary table of evidence from the systematic review examining the effect of co-trimoxazole on the morbidity",
      "page": 22,
      "pageLabel": "19",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "7",
      "title": "Implementation considerations for co-trimoxazole prophylaxis Co-trimoxazole prophylaxis may be discontinued at the end of the at-risk period for HIV transmission (after",
      "page": 23,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "6",
      "title": "Components of nurturing care",
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "8",
      "title": "WHO recommendations for nurturing care Responsive caregiving",
      "page": 24,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "Photograph, seen from behind, of a woman in a turquoise dress carrying an infant in a red knitted hat and blue blanket over her shoulder; the infant looks at the camera.",
        "ar": "صورة فوتوغرافية، من الخلف، لامرأة ترتدي ثوباً فيروزياً وتحمل على كتفها رضيعاً يعتمر قبعة حمراء محبوكة وملفوفاً ببطانية زرقاء؛ وينظر الرضيع إلى الكاميرا.",
        "zh": "照片（背面视角）：一名身穿青绿色连衣裙的妇女将一名戴红色针织帽、裹着蓝色毯子的婴儿抱在肩上，婴儿望向镜头。",
        "es": "Fotografía, de espaldas, de una mujer con vestido turquesa que lleva sobre el hombro a un lactante con gorro rojo de punto y manta azul; el lactante mira a la cámara.",
        "fr": "Photographie, de dos, d'une femme en robe turquoise portant sur l'épaule un nourrisson coiffé d'un bonnet rouge en tricot et enveloppé d'une couverture bleue ; le nourrisson regarde l'objectif.",
        "ru": "Фотография со спины: женщина в бирюзовом платье несёт на плече младенца в красной вязаной шапке и синем одеяле; младенец смотрит в камеру."
      },
      "state": "draft"
    },
    {
      "id": "img-p007-1",
      "file": "images/img-p007-1.webp",
      "page": 7,
      "narratives": {
        "en": "Photograph of a smiling woman pressing her cheek against a baby in an orange outfit whom she holds up.",
        "ar": "صورة فوتوغرافية لامرأة مبتسمة تضع خدها على خد رضيعة ترتدي ثوباً برتقالياً وتحملها.",
        "zh": "照片：一名面带微笑的妇女抱着一名身穿橙色衣服的婴儿，脸颊贴着婴儿的脸颊。",
        "es": "Fotografía de una mujer sonriente que apoya la mejilla contra la de un bebé vestido de naranja al que sostiene en brazos.",
        "fr": "Photographie d'une femme souriante, joue contre joue avec un bébé vêtu d'orange qu'elle tient dans ses bras.",
        "ru": "Фотография улыбающейся женщины, прижавшейся щекой к младенцу в оранжевой одежде, которого она держит на руках."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p007",
      "file": "figures/vfig-p007.webp",
      "page": 7,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Figure 1, a target (bullseye) diagram with six arrows pointing to its centre, each labelled with a component of the comprehensive package of care for infants and young children exposed to HIV: infant diagnosis, postnatal care, postnatal prophylaxis, maternal testing, treatment and monitoring, nurturing care, and co-trimoxazole. Each label carries a short description, e.g. timely provision of co-trimoxazole to prevent Pneumocystis jirovecii pneumonia and mortality among infants and children living with HIV.",
        "ar": "الشكل 1، مخطط على شكل هدف تتجه إلى مركزه ستة أسهم، يحمل كل منها أحد مكونات حزمة الرعاية الشاملة للرضّع وصغار الأطفال المعرّضين لفيروس العوز المناعي البشري: تشخيص الرضّع، والرعاية بعد الولادة، والوقاية بعد الولادة، واختبار الأمهات وعلاجهن ورصدهن، والرعاية التنموية، والكوتريموكسازول. ويرافق كل عنوان وصف موجز، مثل توفير الكوتريموكسازول في الوقت المناسب للوقاية من الالتهاب الرئوي بالمتكيسة الرئوية الجيروفيسية والوفيات بين الرضّع والأطفال المصابين بالفيروس.",
        "zh": "图1：靶心图，六个箭头指向中心，每个箭头标注接触艾滋病毒的婴幼儿综合照护包的一个组成部分：婴儿诊断、产后护理、产后预防、孕产妇检测、治疗和监测、养育照护以及复方新诺明。每个标签附有简短说明，例如及时提供复方新诺明，以预防感染艾滋病毒婴儿和儿童的耶氏肺孢子菌肺炎和死亡。",
        "es": "Figura 1, diagrama en forma de diana con seis flechas dirigidas al centro, cada una rotulada con un componente del paquete integral de atención para lactantes y niños pequeños expuestos al VIH: diagnóstico del lactante, atención posnatal, profilaxis posnatal, pruebas, tratamiento y seguimiento maternos, cuidado cariñoso y sensible, y cotrimoxazol. Cada rótulo incluye una breve descripción, p. ej., la administración oportuna de cotrimoxazol para prevenir la neumonía por Pneumocystis jirovecii y la mortalidad entre lactantes y niños con el VIH.",
        "fr": "Figure 1, diagramme en forme de cible vers le centre de laquelle pointent six flèches, chacune portant une composante de l'ensemble complet de soins pour les nourrissons et jeunes enfants exposés au VIH : diagnostic du nourrisson, soins postnatals, prophylaxie postnatale, dépistage, traitement et suivi maternels, soins attentifs, et cotrimoxazole. Chaque intitulé est accompagné d'une brève description, par exemple la fourniture en temps utile de cotrimoxazole pour prévenir la pneumonie à Pneumocystis jirovecii et la mortalité chez les nourrissons et enfants vivant avec le VIH.",
        "ru": "Рисунок 1 — диаграмма в виде мишени с шестью стрелками, направленными в центр; каждая подписана одним из компонентов комплексного пакета помощи младенцам и детям раннего возраста, подвергшимся воздействию ВИЧ: диагностика у младенцев, послеродовой уход, послеродовая профилактика, тестирование, лечение и мониторинг матерей, благоприятный уход и котримоксазол. К каждой подписи дано краткое пояснение, например своевременное назначение котримоксазола для профилактики пневмоцистной пневмонии (Pneumocystis jirovecii) и смертности среди младенцев и детей, живущих с ВИЧ."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p008",
      "file": "figures/vfig-p008.webp",
      "page": 8,
      "shows": [
        "Figure 2"
      ],
      "narratives": {
        "en": "Figure 2, a timeline from 34–36 weeks' gestation to 24 months showing when each service is delivered: viral load tests for mothers living with HIV, retesting of HIV-negative high-risk mothers, and for exposed infants infant diagnosis (ID: nucleic acid tests at birth, 6 weeks and 9 months, serology at 18 months), co-trimoxazole (CTX), postnatal prophylaxis (PNP) for high- and low-risk infants, nurturing care (NC) and routine immunization and monitoring. Text boxes note that HIV infection is excluded with an appropriate test 3 months after stopping breastfeeding, and that co-trimoxazole and extended PNP may be stopped once HIV infection is excluded at the end of the at-risk period.",
        "ar": "الشكل 2، خط زمني يمتد من الأسبوع 34–36 من الحمل إلى 24 شهراً، يبيّن مواعيد تقديم كل خدمة: اختبارات الحمل الفيروسي للأمهات المصابات بفيروس العوز المناعي البشري، وإعادة اختبار الأمهات السلبيات للفيروس المعرّضات لخطر شديد، وللرضّع المعرّضين: تشخيص الرضّع (اختبارات الأحماض النووية عند الولادة وفي الأسبوع 6 والشهر 9، والاختبار المصلي في الشهر 18)، والكوتريموكسازول، والوقاية بعد الولادة للرضّع الشديدي الخطر والمنخفضي الخطر، والرعاية التنموية، والتمنيع والرصد الروتينيين. وتشير مربعات نصية إلى استبعاد العدوى بالفيروس باختبار مناسب بعد 3 أشهر من التوقف عن الرضاعة الطبيعية، وإلى جواز وقف الكوتريموكسازول والوقاية الممتدة بعد استبعاد العدوى في نهاية فترة الخطر.",
        "zh": "图2：从妊娠34–36周到24个月的时间线，显示各项服务的提供时间：感染艾滋病毒母亲的病毒载量检测、艾滋病毒阴性高风险母亲的重复检测，以及针对暴露婴儿的婴儿诊断（出生时、6周和9个月进行核酸检测，18个月进行血清学检测）、复方新诺明、高风险和低风险婴儿的产后预防、养育照护以及常规免疫和监测。文本框说明，停止母乳喂养3个月后用适当检测排除艾滋病毒感染；在风险期结束时排除感染后，可停用复方新诺明和延长的产后预防。",
        "es": "Figura 2, cronograma desde las 34–36 semanas de gestación hasta los 24 meses que muestra cuándo se presta cada servicio: pruebas de carga viral para madres con el VIH, repetición de pruebas en madres seronegativas de alto riesgo y, para los lactantes expuestos, diagnóstico del lactante (pruebas de ácidos nucleicos al nacer, a las 6 semanas y a los 9 meses; serología a los 18 meses), cotrimoxazol, profilaxis posnatal para lactantes de alto y bajo riesgo, cuidado cariñoso y sensible, e inmunización y seguimiento sistemáticos. Unos recuadros indican que la infección por el VIH se descarta con una prueba adecuada 3 meses después de suspender la lactancia materna, y que el cotrimoxazol y la profilaxis posnatal ampliada pueden suspenderse una vez descartada la infección al final del periodo de riesgo.",
        "fr": "Figure 2, chronologie allant de 34–36 semaines de grossesse à 24 mois, indiquant quand chaque service est fourni : tests de charge virale pour les mères vivant avec le VIH, nouveau dépistage des mères séronégatives à haut risque et, pour les nourrissons exposés, diagnostic du nourrisson (tests d'acides nucléiques à la naissance, à 6 semaines et à 9 mois ; sérologie à 18 mois), cotrimoxazole, prophylaxie postnatale pour les nourrissons à haut et faible risque, soins attentifs, et vaccination et suivi systématiques. Des encadrés précisent que l'infection à VIH est exclue par un test approprié 3 mois après l'arrêt de l'allaitement, et que le cotrimoxazole et la prophylaxie postnatale prolongée peuvent être arrêtés une fois l'infection exclue à la fin de la période à risque.",
        "ru": "Рисунок 2 — временная шкала от 34–36 недель беременности до 24 месяцев, показывающая сроки оказания каждой услуги: тесты на вирусную нагрузку для матерей, живущих с ВИЧ, повторное тестирование ВИЧ-отрицательных матерей группы высокого риска, а для подвергшихся воздействию младенцев — диагностика (тесты на нуклеиновые кислоты при рождении, в 6 недель и 9 месяцев; серологический тест в 18 месяцев), котримоксазол, послеродовая профилактика для младенцев высокого и низкого риска, благоприятный уход, плановая иммунизация и наблюдение. В текстовых блоках указано, что ВИЧ-инфекция исключается соответствующим тестом через 3 месяца после прекращения грудного вскармливания и что котримоксазол и расширенную послеродовую профилактику можно прекратить после исключения инфекции в конце периода риска."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p009",
      "file": "figures/vfig-p009.webp",
      "page": 9,
      "shows": [
        "Figure 3"
      ],
      "narratives": {
        "en": "Figure 3, a flow diagram (printed rotated on the page) of how the components of the package change after a child acquires HIV. Five components (ID, CTX, PNP, NC, Routine) lead into 'HIV-positive diagnosis', after which ART starts and continues lifelong; co-trimoxazole continues for all infants and children to 5 years of age; nurturing-care interventions run to 3, 5 and 8 years of age; and routine services to 2 years. After age 5, co-trimoxazole continues in settings with a high prevalence of malaria and severe bacterial infections (reassessment in adulthood) and may be discontinued in low-prevalence settings if the child is on ART, stable and virally suppressed.",
        "ar": "الشكل 3، مخطط انسيابي (مطبوع بشكل مُدار على الصفحة) يبيّن كيف تتغير مكونات الحزمة بعد إصابة الطفل بفيروس العوز المناعي البشري. تؤدي خمسة مكونات (تشخيص الرضّع، والكوتريموكسازول، والوقاية بعد الولادة، والرعاية التنموية، والخدمات الروتينية) إلى \"تشخيص إيجابي للفيروس\"، يبدأ بعده العلاج بمضادات الفيروسات القهقرية ويستمر مدى الحياة؛ ويستمر الكوتريموكسازول لجميع الرضّع والأطفال حتى سن 5 سنوات؛ وتمتد تدخلات الرعاية التنموية حتى سن 3 و5 و8 سنوات؛ والخدمات الروتينية حتى سن سنتين. وبعد سن 5 سنوات، يستمر الكوتريموكسازول في الأماكن التي ترتفع فيها معدلات الملاريا والعداوى البكتيرية الوخيمة (مع إعادة التقييم في سن البلوغ)، ويجوز وقفه في الأماكن المنخفضة الانتشار إذا كان الطفل يتلقى العلاج ومستقراً ومكبوت الحمل الفيروسي.",
        "zh": "图3：流程图（在页面上旋转印刷），显示儿童感染艾滋病毒后照护包各组成部分的变化。五个组成部分（婴儿诊断、复方新诺明、产后预防、养育照护、常规服务）指向“艾滋病毒阳性诊断”，此后开始抗逆转录病毒治疗并终身持续；所有婴儿和儿童持续使用复方新诺明至5岁；养育照护干预持续至3岁、5岁和8岁；常规服务持续至2岁。5岁以后，在疟疾和严重细菌感染高流行地区继续使用复方新诺明（成年后重新评估）；在低流行地区，如儿童正在接受抗逆转录病毒治疗、病情稳定且病毒得到抑制，可停用。",
        "es": "Figura 3, diagrama de flujo (impreso girado en la página) que muestra cómo cambian los componentes del paquete cuando un niño contrae el VIH. Cinco componentes (diagnóstico del lactante, cotrimoxazol, profilaxis posnatal, cuidado cariñoso y sensible, y servicios sistemáticos) conducen a «Diagnóstico positivo del VIH», tras el cual se inicia el TAR, que se mantiene de por vida; el cotrimoxazol continúa para todos los lactantes y niños hasta los 5 años; las intervenciones de cuidado cariñoso se prolongan hasta los 3, 5 y 8 años; y los servicios sistemáticos, hasta los 2 años. Después de los 5 años, el cotrimoxazol continúa en entornos con alta prevalencia de paludismo e infecciones bacterianas graves (con reevaluación en la edad adulta) y puede suspenderse en entornos de baja prevalencia si el niño recibe TAR, está estable y tiene supresión viral.",
        "fr": "Figure 3, logigramme (imprimé pivoté sur la page) montrant comment les composantes de l'ensemble de soins évoluent lorsqu'un enfant contracte le VIH. Cinq composantes (diagnostic du nourrisson, cotrimoxazole, prophylaxie postnatale, soins attentifs et services systématiques) mènent au « Diagnostic positif du VIH », après lequel le TAR est instauré et poursuivi à vie ; le cotrimoxazole est maintenu pour tous les nourrissons et enfants jusqu'à 5 ans ; les interventions de soins attentifs se poursuivent jusqu'à 3, 5 et 8 ans ; et les services systématiques jusqu'à 2 ans. Après 5 ans, le cotrimoxazole est maintenu dans les contextes de forte prévalence du paludisme et des infections bactériennes graves (réévaluation à l'âge adulte) et peut être arrêté dans les contextes de faible prévalence si l'enfant est sous TAR, stable et en suppression virale.",
        "ru": "Рисунок 3 — блок-схема (напечатанная на странице с поворотом), показывающая, как меняются компоненты пакета после заражения ребёнка ВИЧ. Пять компонентов (диагностика у младенцев, котримоксазол, послеродовая профилактика, благоприятный уход, плановые услуги) ведут к блоку «Положительный диагноз ВИЧ», после чего начинается АРТ, продолжающаяся пожизненно; котримоксазол продолжают всем младенцам и детям до 5 лет; меры благоприятного ухода — до 3, 5 и 8 лет; плановые услуги — до 2 лет. После 5 лет котримоксазол продолжают в условиях высокой распространённости малярии и тяжёлых бактериальных инфекций (с пересмотром во взрослом возрасте), а в условиях низкой распространённости его можно отменить, если ребёнок получает АРТ, стабилен и имеет подавленную вирусную нагрузку."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p010",
      "file": "figures/vfig-p010.webp",
      "page": 10,
      "shows": [
        "Figure 4"
      ],
      "narratives": {
        "en": "Figure 4, a single stacked bar for 2020 (y-axis 0 to 160 000) showing infants acquiring HIV vertically by cause of transmission: mother acquired HIV during pregnancy or breastfeeding, 35 000; mother did not receive antiretroviral therapy during pregnancy or breastfeeding, 65 000; mother did not continue with treatment, 38 000; mother was on antiretroviral therapy but not virally suppressed, 14 000. Source: UNAIDS epidemiological estimates, 2021.",
        "ar": "الشكل 4، عمود مكدّس واحد لعام 2020 (المحور الرأسي من 0 إلى 160 000) يبيّن الرضّع الذين أصيبوا بفيروس العوز المناعي البشري عمودياً حسب سبب الانتقال: إصابة الأم بالفيروس أثناء الحمل أو الرضاعة الطبيعية، 35 000؛ وعدم تلقي الأم العلاج بمضادات الفيروسات القهقرية أثناء الحمل أو الرضاعة، 65 000؛ وعدم مواصلة الأم العلاج، 38 000؛ وتلقي الأم العلاج دون كبت الحمل الفيروسي، 14 000. المصدر: التقديرات الوبائية لبرنامج الأمم المتحدة المشترك المعني بالإيدز، 2021.",
        "zh": "图4：2020年的单个堆积柱形图（纵轴0至160 000），按传播原因显示经垂直传播感染艾滋病毒的婴儿：母亲在妊娠或哺乳期间感染艾滋病毒，35 000；母亲在妊娠或哺乳期间未接受抗逆转录病毒治疗，65 000；母亲未持续治疗，38 000；母亲接受抗逆转录病毒治疗但病毒未得到抑制，14 000。来源：联合国艾滋病规划署2021年流行病学估计。",
        "es": "Figura 4, una sola barra apilada para 2020 (eje vertical de 0 a 160 000) que muestra los lactantes que contrajeron el VIH por transmisión vertical según la causa: la madre contrajo el VIH durante el embarazo o la lactancia, 35 000; la madre no recibió tratamiento antirretroviral durante el embarazo o la lactancia, 65 000; la madre no continuó el tratamiento, 38 000; la madre recibía tratamiento antirretroviral pero sin supresión viral, 14 000. Fuente: estimaciones epidemiológicas del ONUSIDA, 2021.",
        "fr": "Figure 4, une seule barre empilée pour 2020 (axe vertical de 0 à 160 000) montrant les nourrissons ayant contracté le VIH par transmission verticale, selon la cause : la mère a contracté le VIH pendant la grossesse ou l'allaitement, 35 000 ; la mère n'a pas reçu de traitement antirétroviral pendant la grossesse ou l'allaitement, 65 000 ; la mère n'a pas poursuivi le traitement, 38 000 ; la mère était sous traitement antirétroviral sans suppression virale, 14 000. Source : estimations épidémiologiques de l'ONUSIDA, 2021.",
        "ru": "Рисунок 4 — один столбец с накоплением за 2020 год (вертикальная ось от 0 до 160 000), показывающий младенцев, заразившихся ВИЧ вертикальным путём, по причинам передачи: мать заразилась ВИЧ во время беременности или грудного вскармливания — 35 000; мать не получала антиретровирусную терапию во время беременности или грудного вскармливания — 65 000; мать не продолжила лечение — 38 000; мать получала антиретровирусную терапию, но без подавления вирусной нагрузки — 14 000. Источник: эпидемиологические оценки ЮНЭЙДС, 2021 год."
      },
      "state": "draft"
    },
    {
      "id": "img-p014-1",
      "file": "images/img-p014-1.webp",
      "page": 14,
      "narratives": {
        "en": "Photograph of a woman in an orange headscarf and a blue face mask holding a baby in a white shirt.",
        "ar": "صورة فوتوغرافية لامرأة ترتدي وشاحاً برتقالياً للرأس وكمامة زرقاء وتحمل رضيعاً يرتدي قميصاً أبيض.",
        "zh": "照片：一名头戴橙色头巾、佩戴蓝色口罩的妇女抱着一名身穿白色上衣的婴儿。",
        "es": "Fotografía de una mujer con pañuelo naranja en la cabeza y mascarilla azul que sostiene a un bebé con camisa blanca.",
        "fr": "Photographie d'une femme portant un foulard orange et un masque bleu, tenant un bébé en chemise blanche.",
        "ru": "Фотография женщины в оранжевом платке и синей маске, держащей младенца в белой рубашке."
      },
      "state": "draft"
    },
    {
      "id": "img-p016-1",
      "file": "images/img-p016-1.webp",
      "page": 16,
      "narratives": {
        "en": "Photograph of a woman in a black head wrap and patterned pink dress holding a toddler who is eating from a packet, in front of a corrugated metal wall.",
        "ar": "صورة فوتوغرافية لامرأة تعتمر غطاء رأس أسود وترتدي ثوباً وردياً مزخرفاً وتحمل طفلاً صغيراً يأكل من كيس، أمام جدار من الصفيح المموّج.",
        "zh": "照片：一名头裹黑色头巾、身穿粉色花纹连衣裙的妇女在波纹铁皮墙前抱着一名正从小袋中吃东西的幼儿。",
        "es": "Fotografía de una mujer con turbante negro y vestido rosa estampado que sostiene a un niño pequeño que come de un sobre, delante de una pared de chapa ondulada.",
        "fr": "Photographie d'une femme coiffée d'un foulard noir et vêtue d'une robe rose à motifs, tenant un jeune enfant qui mange dans un sachet, devant un mur en tôle ondulée.",
        "ru": "Фотография женщины в чёрном головном уборе и розовом узорчатом платье, держащей малыша, который ест из пакетика, на фоне стены из гофрированного металла."
      },
      "state": "draft"
    },
    {
      "id": "img-p017-1",
      "file": "images/img-p017-1.webp",
      "page": 17,
      "narratives": {
        "en": "Photograph of a woman in a red patterned headscarf and a yellow cloth mask holding a smiling baby in a home, with shelves and a 2020 wall calendar behind them.",
        "ar": "صورة فوتوغرافية لامرأة ترتدي وشاحاً أحمر مزخرفاً للرأس وكمامة قماشية صفراء وتحمل رضيعاً مبتسماً في منزل، وخلفهما رفوف وتقويم جداري لعام 2020.",
        "zh": "照片：一名头戴红色花纹头巾、佩戴黄色布口罩的妇女在家中抱着一名微笑的婴儿，身后有搁架和一本2020年挂历。",
        "es": "Fotografía de una mujer con pañuelo rojo estampado y mascarilla de tela amarilla que sostiene a un bebé sonriente en una vivienda, con estantes y un calendario de pared de 2020 detrás.",
        "fr": "Photographie d'une femme portant un foulard rouge à motifs et un masque en tissu jaune, tenant un bébé souriant dans un logement, avec des étagères et un calendrier mural 2020 derrière eux.",
        "ru": "Фотография женщины в красном узорчатом платке и жёлтой тканевой маске, держащей улыбающегося младенца у себя дома; позади полки и настенный календарь на 2020 год."
      },
      "state": "draft"
    },
    {
      "id": "img-p018-1",
      "file": "images/img-p018-1.webp",
      "page": 18,
      "narratives": {
        "en": "Photograph of a woman in a pink headscarf holding a baby in a white cap and striped top.",
        "ar": "صورة فوتوغرافية لامرأة ترتدي وشاحاً وردياً للرأس وتحمل رضيعاً يعتمر قبعة بيضاء ويرتدي قميصاً مخططاً.",
        "zh": "照片：一名头戴粉色头巾的妇女抱着一名戴白色帽子、身穿条纹上衣的婴儿。",
        "es": "Fotografía de una mujer con pañuelo rosa en la cabeza que sostiene a un bebé con gorro blanco y camiseta a rayas.",
        "fr": "Photographie d'une femme portant un foulard rose, tenant un bébé coiffé d'un bonnet blanc et vêtu d'un haut rayé.",
        "ru": "Фотография женщины в розовом платке, держащей младенца в белой шапочке и полосатой кофточке."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p018",
      "file": "figures/vfig-p018.webp",
      "page": 18,
      "shows": [
        "Figure 5"
      ],
      "narratives": {
        "en": "Figure 5, a decision tree starting from 'Assess mother at delivery'. Infants are classed as high risk if the mother is a known HIV-positive mother not on ART, is newly identified as HIV-positive within 72 hours of delivery, or is on ART with a viral load above 1000 within 4 weeks before delivery; they are low risk if the viral load is at or below 1000. If no viral load result is available, infants are low risk when the mother has been on ART for more than 4 weeks before delivery and high risk otherwise.",
        "ar": "الشكل 5، شجرة قرارات تبدأ بـ\"تقييم الأم عند الولادة\". يُصنَّف الرضّع على أنهم شديدو الخطر إذا كانت الأم معروفة بإصابتها بفيروس العوز المناعي البشري ولا تتلقى العلاج بمضادات الفيروسات القهقرية، أو اكتُشفت إصابتها حديثاً في غضون 72 ساعة من الولادة، أو كانت تتلقى العلاج وحملها الفيروسي أعلى من 1000 في غضون 4 أسابيع قبل الولادة؛ ومنخفضو الخطر إذا كان الحمل الفيروسي 1000 أو أقل. وإذا لم تتوافر نتيجة للحمل الفيروسي، يكون الرضّع منخفضي الخطر إذا كانت الأم تتلقى العلاج منذ أكثر من 4 أسابيع قبل الولادة، وشديدي الخطر خلاف ذلك.",
        "zh": "图5：决策树，起点为“分娩时评估母亲”。如母亲为已知艾滋病毒阳性但未接受抗逆转录病毒治疗、在分娩72小时内新确诊为艾滋病毒阳性，或正在接受治疗但分娩前4周内病毒载量高于1000，则婴儿归为高风险；如病毒载量不高于1000，则为低风险。如无病毒载量结果，母亲在分娩前已接受治疗超过4周的，婴儿为低风险，否则为高风险。",
        "es": "Figura 5, árbol de decisiones que comienza con «Evaluar a la madre en el parto». Los lactantes se clasifican como de alto riesgo si la madre es seropositiva conocida sin TAR, se le detecta el VIH en las 72 horas siguientes al parto, o recibe TAR con una carga viral superior a 1000 en las 4 semanas previas al parto; son de bajo riesgo si la carga viral es igual o inferior a 1000. Si no se dispone de resultado de carga viral, los lactantes son de bajo riesgo cuando la madre lleva más de 4 semanas en TAR antes del parto, y de alto riesgo en caso contrario.",
        "fr": "Figure 5, arbre de décision partant de « Évaluer la mère à l'accouchement ». Les nourrissons sont classés à haut risque si la mère est séropositive connue sans TAR, est nouvellement identifiée comme séropositive dans les 72 heures suivant l'accouchement, ou est sous TAR avec une charge virale supérieure à 1000 dans les 4 semaines précédant l'accouchement ; ils sont à faible risque si la charge virale est inférieure ou égale à 1000. En l'absence de résultat de charge virale, les nourrissons sont à faible risque si la mère est sous TAR depuis plus de 4 semaines avant l'accouchement, et à haut risque sinon.",
        "ru": "Рисунок 5 — дерево решений, начинающееся с блока «Оценить мать при родах». Младенцы относятся к группе высокого риска, если мать — известная ВИЧ-положительная женщина, не получающая АРТ, впервые выявлена как ВИЧ-положительная в течение 72 часов после родов или получает АРТ с вирусной нагрузкой выше 1000 в течение 4 недель до родов; к группе низкого риска — если вирусная нагрузка не превышает 1000. При отсутствии результата вирусной нагрузки младенцы относятся к группе низкого риска, если мать получала АРТ более 4 недель до родов, и к группе высокого риска в противном случае."
      },
      "state": "draft"
    },
    {
      "id": "img-p020-1",
      "file": "images/img-p020-1.webp",
      "page": 20,
      "narratives": {
        "en": "Photograph of a woman leaning over a toddler girl who holds pink and orange plastic cups, against a blue background.",
        "ar": "صورة فوتوغرافية لامرأة تنحني فوق طفلة صغيرة تحمل كوبين بلاستيكيين وردياً وبرتقالياً، على خلفية زرقاء.",
        "zh": "照片：一名妇女俯身靠近一名手持粉色和橙色塑料杯的幼女，背景为蓝色。",
        "es": "Fotografía de una mujer inclinada sobre una niña pequeña que sostiene vasos de plástico rosa y naranja, con fondo azul.",
        "fr": "Photographie d'une femme penchée sur une fillette qui tient des gobelets en plastique rose et orange, sur fond bleu.",
        "ru": "Фотография женщины, склонившейся над маленькой девочкой с розовым и оранжевым пластиковыми стаканчиками, на синем фоне."
      },
      "state": "draft"
    },
    {
      "id": "img-p024-1",
      "file": "images/img-p024-1.webp",
      "page": 24,
      "narratives": {
        "en": "Figure 6: Circular diagram of the five components of nurturing care around the central label 'Components of nurturing care': good health (green, heart icon), adequate nutrition (gold, bowl icon), responsive caregiving (blue, parents holding a baby), security and safety (dark blue, family under a sheltering arm) and opportunities for early learning (red, child playing).",
        "ar": "الشكل 6: مخطط دائري للمكونات الخمسة للرعاية التنموية حول العنوان المركزي \"مكونات الرعاية التنموية\": الصحة الجيدة (أخضر، أيقونة قلب)، والتغذية الكافية (ذهبي، أيقونة وعاء)، والرعاية المستجيبة (أزرق، والدان يحملان رضيعاً)، والأمن والسلامة (أزرق داكن، أسرة تحت ذراع حامية)، وفرص التعلم المبكر (أحمر، طفل يلعب).",
        "zh": "图6：圆形图，围绕中心标签“养育照护的组成部分”展示五个组成部分：良好健康（绿色，心形图标）、充足营养（金色，碗形图标）、回应性照护（蓝色，父母抱着婴儿）、安全保障（深蓝色，手臂庇护下的家庭）以及早期学习机会（红色，玩耍的儿童）。",
        "es": "Figura 6: Diagrama circular de los cinco componentes del cuidado cariñoso y sensible en torno a la etiqueta central «Componentes del cuidado cariñoso y sensible»: buena salud (verde, icono de corazón), nutrición adecuada (dorado, icono de cuenco), atención receptiva (azul, padres con un bebé en brazos), protección y seguridad (azul oscuro, familia bajo un brazo protector) y oportunidades de aprendizaje temprano (rojo, niño jugando).",
        "fr": "Figure 6 : Diagramme circulaire des cinq composantes des soins attentifs autour de l'intitulé central « Composantes des soins attentifs » : bonne santé (vert, icône de cœur), nutrition adéquate (doré, icône de bol), soins réactifs (bleu, parents tenant un bébé), sécurité et sûreté (bleu foncé, famille sous un bras protecteur) et possibilités d'apprentissage précoce (rouge, enfant qui joue).",
        "ru": "Рисунок 6: Круговая диаграмма пяти компонентов благоприятного ухода вокруг центральной надписи «Компоненты благоприятного ухода»: хорошее здоровье (зелёный, значок сердца), полноценное питание (золотистый, значок миски), чуткий уход (синий, родители с младенцем на руках), защищённость и безопасность (тёмно-синий, семья под защищающей рукой) и возможности для раннего обучения (красный, играющий ребёнок)."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p024",
      "file": "figures/vfig-p024.webp",
      "page": 24,
      "shows": [
        "Figure 6"
      ],
      "narratives": {
        "en": "Figure 6: Circular diagram of the five components of nurturing care around the central label 'Components of nurturing care': good health (green, heart icon), adequate nutrition (gold, bowl icon), responsive caregiving (blue, parents holding a baby), security and safety (dark blue, family under a sheltering arm) and opportunities for early learning (red, child playing).",
        "ar": "الشكل 6: مخطط دائري للمكونات الخمسة للرعاية التنموية حول العنوان المركزي \"مكونات الرعاية التنموية\": الصحة الجيدة (أخضر، أيقونة قلب)، والتغذية الكافية (ذهبي، أيقونة وعاء)، والرعاية المستجيبة (أزرق، والدان يحملان رضيعاً)، والأمن والسلامة (أزرق داكن، أسرة تحت ذراع حامية)، وفرص التعلم المبكر (أحمر، طفل يلعب).",
        "zh": "图6：圆形图，围绕中心标签“养育照护的组成部分”展示五个组成部分：良好健康（绿色，心形图标）、充足营养（金色，碗形图标）、回应性照护（蓝色，父母抱着婴儿）、安全保障（深蓝色，手臂庇护下的家庭）以及早期学习机会（红色，玩耍的儿童）。",
        "es": "Figura 6: Diagrama circular de los cinco componentes del cuidado cariñoso y sensible en torno a la etiqueta central «Componentes del cuidado cariñoso y sensible»: buena salud (verde, icono de corazón), nutrición adecuada (dorado, icono de cuenco), atención receptiva (azul, padres con un bebé en brazos), protección y seguridad (azul oscuro, familia bajo un brazo protector) y oportunidades de aprendizaje temprano (rojo, niño jugando).",
        "fr": "Figure 6 : Diagramme circulaire des cinq composantes des soins attentifs autour de l'intitulé central « Composantes des soins attentifs » : bonne santé (vert, icône de cœur), nutrition adéquate (doré, icône de bol), soins réactifs (bleu, parents tenant un bébé), sécurité et sûreté (bleu foncé, famille sous un bras protecteur) et possibilités d'apprentissage précoce (rouge, enfant qui joue).",
        "ru": "Рисунок 6: Круговая диаграмма пяти компонентов благоприятного ухода вокруг центральной надписи «Компоненты благоприятного ухода»: хорошее здоровье (зелёный, значок сердца), полноценное питание (золотистый, значок миски), чуткий уход (синий, родители с младенцем на руках), защищённость и безопасность (тёмно-синий, семья под защищающей рукой) и возможности для раннего обучения (красный, играющий ребёнок)."
      },
      "state": "draft"
    },
    {
      "id": "img-p034-1",
      "file": "images/img-p034-1.webp",
      "page": 34,
      "narratives": {
        "en": "ISBN barcode with the number 9789240040236.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) يحمل الرقم 9789240040236.",
        "zh": "国际标准书号（ISBN）条形码，编号为9789240040236。",
        "es": "Código de barras del ISBN con el número 9789240040236.",
        "fr": "Code-barres ISBN portant le numéro 9789240040236.",
        "ru": "Штрихкод ISBN с номером 9789240040236."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Recommended times for HIV retesting for pregnant and postpartum women",
      "pages": [
        12
      ],
      "columns": [
        {
          "titles": "Setting"
        },
        {
          "titles": "Early in pregnancy (first antenatal care visit)",
          "group": "Time points"
        },
        {
          "titles": "Late in pregnancy (third-trimester antenatal care visit)",
          "group": "Time points"
        },
        {
          "titles": "One additional postpartum retest (14 weeks, 6 months or 9 months postpartum)",
          "group": "Time points"
        }
      ],
      "rows": [
        [
          "Settings with a high HIV burden",
          "All",
          "All",
          "Can be considered for those with ongoing high risk"
        ],
        [
          "Settings with a low HIV burden",
          "All pregnant women as part of eliminating vertical transmission, otherwise focused on those with high ongoing risk",
          "Can be considered for those with high ongoing risk",
          "Can be considered for those with high ongoing risk"
        ],
        [
          "Among key population groups and their partners",
          "All settings",
          "All settings",
          "All settings"
        ]
      ],
      "notes": "Source: WHO consolidated guidelines on HIV testing services, 2019 (29).",
      "narratives": {
        "en": "Recommended time points for HIV retesting of pregnant and postpartum women (early pregnancy, late pregnancy, one additional postpartum retest) in settings with a high HIV burden, settings with a low HIV burden, and among key population groups and their partners.",
        "ar": "التوقيتات الموصى بها لإعادة اختبار فيروس العوز المناعي البشري لدى الحوامل والنساء في فترة ما بعد الولادة (في بداية الحمل، وفي أواخره، وإعادة اختبار إضافية بعد الولادة) في المواقع ذات العبء المرتفع للفيروس، والمواقع ذات العبء المنخفض، وبين الفئات السكانية الرئيسية وشركائها.",
        "zh": "孕产妇艾滋病毒复检的推荐时间点（妊娠早期、妊娠晚期、产后一次额外复检），分别针对艾滋病毒高负担地区、低负担地区以及重点人群及其伴侣。",
        "es": "Momentos recomendados para repetir la prueba del VIH en embarazadas y puérperas (al inicio del embarazo, al final del embarazo y una prueba adicional posparto) en entornos con alta carga de VIH, entornos con baja carga de VIH y entre los grupos de población clave y sus parejas.",
        "fr": "Moments recommandés pour refaire le test VIH chez les femmes enceintes et en post-partum (début de grossesse, fin de grossesse, un test supplémentaire en post-partum) dans les contextes à forte charge de VIH, à faible charge de VIH et parmi les groupes de population clés et leurs partenaires.",
        "ru": "Рекомендуемые сроки повторного тестирования на ВИЧ беременных и родильниц (в начале беременности, в конце беременности и одно дополнительное повторное тестирование после родов) в условиях высокого и низкого бремени ВИЧ, а также среди ключевых групп населения и их партнёров."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Monitoring treatment for pregnant and breastfeeding women",
      "pages": [
        13
      ],
      "columns": [
        {
          "titles": "Category"
        },
        {
          "titles": "Timing of viral load monitoring"
        },
        {
          "titles": "Action"
        }
      ],
      "rows": [
        [
          "Pregnant women receiving ART before conception",
          "First antenatal care visit (or when first presenting)",
          "• If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig.5) and consider infant nucleic acid testing at birth if available"
        ],
        [
          "Pregnant women starting ART during pregnancy",
          "Three months after initiating ART",
          "• If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig. 5) • Regardless of maternal viral load, infants born to women starting ART at any time during pregnancy could be considered for birth testing if available"
        ],
        [
          "All pregnant women, regardless of ART initiation timing",
          "34–36 weeks of gestation (or at the latest at delivery)",
          "• If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig. 5) and provide enhanced postnatal prophylaxis for the infant"
        ],
        [
          "All breastfeeding women, regardless of when ART was initiated",
          "Three months after delivery and every six months thereafter",
          "• If viral load >1000 copies/mL, follow the treatment monitoring algorithm (Fig.5), conduct infant HIV testing immediately and consider reinitiating enhanced postnatal prophylaxis for the infant"
        ]
      ],
      "notes": "Source: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update (2).",
      "narratives": {
        "en": "Viral load monitoring for pregnant and breastfeeding women on ART: for each category of woman the table gives when viral load should be measured and what action to take if it exceeds 1000 copies/mL, including infant testing and postnatal prophylaxis.",
        "ar": "رصد الحمل الفيروسي لدى الحوامل والمرضعات اللواتي يتلقين العلاج بمضادات الفيروسات القهقرية: يبيّن الجدول لكل فئة من النساء موعد قياس الحمل الفيروسي والإجراء الواجب اتخاذه إذا تجاوز 1000 نسخة/مل، بما في ذلك اختبار الرضيع والوقاية بعد الولادة.",
        "zh": "接受抗逆转录病毒治疗的孕妇和哺乳期妇女的病毒载量监测：表中针对每类妇女给出病毒载量检测时间，以及病毒载量超过1000拷贝/毫升时应采取的行动，包括婴儿检测和产后预防。",
        "es": "Seguimiento de la carga viral en embarazadas y mujeres lactantes que reciben TAR: para cada categoría se indica cuándo medir la carga viral y qué medidas adoptar si supera las 1000 copias/ml, incluidas las pruebas al lactante y la profilaxis posnatal.",
        "fr": "Suivi de la charge virale chez les femmes enceintes et allaitantes sous TAR : pour chaque catégorie, le tableau indique quand mesurer la charge virale et quelles mesures prendre si elle dépasse 1000 copies/ml, notamment le dépistage du nourrisson et la prophylaxie postnatale.",
        "ru": "Мониторинг вирусной нагрузки у беременных и кормящих женщин, получающих АРТ: для каждой категории указано, когда измерять вирусную нагрузку и какие меры принимать при её превышении 1000 копий/мл, включая тестирование ребёнка и постнатальную профилактику."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Criteria for initiating and discontinuing co-trimoxazole prophylaxis among children",
      "pages": [
        21
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "Criteria for initiating co-trimoxazole prophylaxis"
        },
        {
          "titles": "Criteria for discontinuing co-trimoxazole prophylaxis"
        }
      ],
      "rows": [
        [
          "Children and adolescents living with HIV",
          "• Initiate for everyone regardless of WHO clinical stage or CD4 cell count • As a priority: – Initiate for everyone younger than five years regardless of WHO clinical stage or CD4 cell count – Initiate for everyone five years and older with severe or advanced HIV disease (WHO clinical stage 3 or 4) or CD4 cell count ≤350 cells/mm3",
          "• In settings with high prevalence of malaria and/or severe bacterial infections: should not be discontinued until adulthood • In settings with low prevalence of both malaria and severe bacterial infections: may be discontinued for those older than five years who are clinically stable, with evidence of immune recoverya and/or suppression of viral loads on ART"
        ],
        [
          "HIV-exposed infants",
          "Initiate for everyone starting at 4–6 weeks after birth",
          "Until the risk of HIV transmission ends and HIV infection is excluded with age-appropriate testb"
        ]
      ],
      "notes": "a Parameter for immune recovery in children older than five years: CD4 cell count >350 cells/mm3, with suppressed viral loads.\nb In settings with low vertical transmission rates, high HIV infant diagnosis coverage and strong retention in the testing-to-treatment cascade, country programmes may consider stopping providing routine co-trimoxazole as soon as HIV infection is ruled out by age-appropriate HIV testing.\nSource: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update (2).",
      "narratives": {
        "en": "Criteria for starting and stopping co-trimoxazole prophylaxis in two populations: children and adolescents living with HIV, and HIV-exposed infants.",
        "ar": "معايير بدء الوقاية بالكوتريموكسازول وإيقافها لدى فئتين: الأطفال والمراهقون المتعايشون مع فيروس العوز المناعي البشري، والرضّع المعرّضون للفيروس.",
        "zh": "两类人群开始和停止复方新诺明预防的标准：感染艾滋病毒的儿童和青少年，以及暴露于艾滋病毒的婴儿。",
        "es": "Criterios para iniciar y suspender la profilaxis con cotrimoxazol en dos poblaciones: niños y adolescentes con el VIH y lactantes expuestos al VIH.",
        "fr": "Critères d’instauration et d’arrêt de la prophylaxie par le cotrimoxazole dans deux populations : les enfants et adolescents vivant avec le VIH et les nourrissons exposés au VIH.",
        "ru": "Критерии начала и прекращения профилактики ко-тримоксазолом для двух групп: детей и подростков, живущих с ВИЧ, и детей грудного возраста, подвергшихся воздействию ВИЧ."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. Summary table of evidence from the systematic review examining the effect of co-trimoxazole on the morbidity and mortality of infants who are HIV-exposed and uninfected",
      "pages": [
        22
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "Co-trimoxazole n"
        },
        {
          "titles": "No co-trimoxazole n"
        },
        {
          "titles": "Mortality"
        },
        {
          "titles": "Hospital admission"
        },
        {
          "titles": "Diarrhoea"
        },
        {
          "titles": "Pneumonia"
        },
        {
          "titles": "Combined outcome*"
        },
        {
          "titles": "Malaria"
        },
        {
          "titles": "Neutropenia"
        },
        {
          "titles": "Anaemia"
        }
      ],
      "rows": [
        [
          "Main studies: key outcomes",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Daniels et al. (53)",
          "South Africa",
          "611",
          "609",
          "↔",
          "N/A",
          "↔",
          "↔",
          "↔",
          "N/A",
          "↔",
          "↔"
        ],
        [
          "Lockman et al. (52)",
          "Botswana",
          "1423",
          "1425",
          "↔",
          "↔",
          "↔",
          "↔",
          "↔",
          "N/A",
          "↑",
          "↔"
        ],
        [
          "Substudies: antibiotic resistance and microbiome",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "D’Souza et al. (55)",
          "South Africa",
          "34",
          "29",
          "Decreased gut microbiome β-diversity and increased antibiotic resistance gene α-diversity and prevalence in the co-trimoxazole group compared with no co-trimoxazole",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Powis et al. (54)",
          "Botswana",
          "105",
          "115",
          "Increased co-trimoxazole-resistant commensal gastrointestinal bacteria in the co-trimoxazole group compared with placebo",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Studies from malarial countries: outcomes (examined continuation of co-trimoxazole prophylaxis after cessation of breastfeeding)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Sandison et al. (56)",
          "Uganda",
          "98",
          "87",
          "↔",
          "↔",
          "↔",
          "↔",
          "N/A",
          "↓",
          "↔",
          "↔"
        ],
        [
          "Homsy et al. (57)",
          "Uganda",
          "45",
          "46",
          "↔",
          "↔",
          "↔",
          "↔",
          "N/A",
          "↓",
          "↔",
          "↔"
        ],
        [
          "Kamya et al. (58)",
          "Uganda",
          "47",
          "46",
          "↔",
          "↔",
          "↔",
          "↔",
          "N/A",
          "↓",
          "N/A",
          "↔‡"
        ]
      ],
      "notes": "Source: PROSPERO 21 CRD42021215059\n↔ No significant difference between co-trimoxazole or placebo / no co-trimoxazole.\n↑ Negative effects of co-trimoxazole prophylaxis.\n↓ Positive effects of co-trimoxazole prophylaxis.\nN/A: not applicable\n* Combined outcome: grade 3 or 4 pneumonia or diarrhoea or all-cause mortality (53); death, admission to hospital or grade 3 or 4 clinical adverse events (52).\n‡ On analysis of safety outcomes, incidence of grade 3 or 4 anaemia was significantly lower in the co-trimoxazole group than in the control group.",
      "narratives": {
        "en": "Evidence from a systematic review on co-trimoxazole prophylaxis in HIV-exposed uninfected infants, grouped into main studies, substudies on antibiotic resistance and microbiome, and studies from malarial countries. For each study the table gives country, numbers in each arm and the direction of effect (no difference, negative or positive) on mortality, hospital admission, diarrhoea, pneumonia, a combined outcome, malaria, neutropenia and anaemia.",
        "ar": "بيّنات من مراجعة منهجية بشأن الوقاية بالكوتريموكسازول لدى الرضّع المعرّضين لفيروس العوز المناعي البشري وغير المصابين به، مقسّمة إلى دراسات رئيسية ودراسات فرعية عن مقاومة المضادات الحيوية والميكروبيوم ودراسات من بلدان موطونة بالملاريا. ويعرض الجدول لكل دراسة البلد وعدد المشاركين في كل ذراع واتجاه الأثر (لا فرق أو سلبي أو إيجابي) على الوفيات ودخول المستشفى والإسهال والالتهاب الرئوي والحصيلة المركّبة والملاريا وقلة العدلات وفقر الدم.",
        "zh": "一项系统综述中关于复方新诺明预防用于暴露于艾滋病毒但未感染婴儿的证据，分为主要研究、关于抗生素耐药性和微生物组的子研究以及来自疟疾流行国家的研究。表中给出每项研究的国家、各组人数，以及对死亡率、住院、腹泻、肺炎、复合结局、疟疾、中性粒细胞减少和贫血的效应方向（无差异、负面或正面）。",
        "es": "Evidencia de una revisión sistemática sobre la profilaxis con cotrimoxazol en lactantes expuestos al VIH y no infectados, agrupada en estudios principales, subestudios sobre resistencia a los antibióticos y microbioma, y estudios de países palúdicos. Para cada estudio se indican el país, el número de participantes en cada grupo y la dirección del efecto (sin diferencia, negativo o positivo) sobre mortalidad, hospitalización, diarrea, neumonía, resultado combinado, malaria, neutropenia y anemia.",
        "fr": "Données d’une revue systématique sur la prophylaxie par le cotrimoxazole chez les nourrissons exposés au VIH et non infectés, regroupées en études principales, sous-études sur la résistance aux antibiotiques et le microbiome, et études menées dans des pays d’endémie palustre. Pour chaque étude, le tableau indique le pays, les effectifs de chaque bras et le sens de l’effet (aucune différence, négatif ou positif) sur la mortalité, l’hospitalisation, la diarrhée, la pneumonie, un critère composite, le paludisme, la neutropénie et l’anémie.",
        "ru": "Данные систематического обзора о профилактике ко-тримоксазолом у детей грудного возраста, подвергшихся воздействию ВИЧ, но не инфицированных, сгруппированные на основные исследования, дополнительные исследования по устойчивости к антибиотикам и микробиому и исследования из эндемичных по малярии стран. Для каждого исследования указаны страна, численность групп и направление эффекта (нет различий, отрицательный или положительный) в отношении смертности, госпитализации, диареи, пневмонии, комбинированного исхода, малярии, нейтропении и анемии."
      },
      "csv": "tables/table-4.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 82,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 77,
      "note": "4 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 15
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 4
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p28); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p4); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 67,
      "note": "67 of 77 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-350214"
  }
}
